がん性疼痛　薬の使い方

出版社： 克誠堂出版
著者：
発行日： 2022-04-21
分野： 臨床医学：外科  >  麻酔科学/ペイン
ISBN： 9784771905610
電子書籍版： 2022-04-21 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,920 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,920 円(税込)

購入する

商品紹介

がん性疼痛治療の薬に特化した一冊。薬物療法における、作用と特徴／適用と種類／臨床投与の実際／副作用／禁忌と注意点などを中心に解説。

目次

  • I　がん性疼痛の発生機序

    II　がん性疼痛に使用される薬剤
    　1．NSAIDs
    　2．アセトアミノフェン　
    　3．コルチコステロイド
    　4．オピオイド
    　　　A. 弱オピオイド
    　　　B. 拮抗性鎮痛薬
    　　　C. 強オピオイド
    　5．がん性疼痛における漢方治療

    III　オピオイド
    　1．がん性疼痛におけるオピオイドの使い方と基本概念
    　2．オピオイドの副作用とその対処
    　3．オピオイドが効きにくい痛みとその治療法
    　　　A. 神経障害性疼痛
    　　　B. 骨転移
    　　　C. オピオイド受容体遺伝子を含む関連遺伝子とオピオイド感受性
    　　　　　―がん性疼痛オピオイド治療の将来へ向けて

    IV　鎮痛補助薬
    　1．抗うつ薬
    　2．抗不安薬
    　3．抗痙攣薬
    　4．抗不整脈薬
    　5．NMDA受容体拮抗薬
    　6．局所麻酔薬、その他

    V　がん性疼痛に対する各種療法
    　1．神経ブロック療法
    　　　A. 交感神経ブロック
    　　　B. 知覚神経ブロック
    　2．脊髄鎮痛法：硬膜外鎮痛法、脊髄くも膜下鎮痛法
    　3．持続皮下注射法
    　4．持続静脈内注射法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I がん性疼痛の発生機序

P.9 掲載の参考文献
1) Portenoy RK. Treatment of cancer pain. Lancet 2011 ; 377 : 2236-47.
PubMed
2) Shaiova L. Difficult pain syndromes : bone pain, visceral pain, and neuropathic pain. Cancer J 2006 ; 12 : 330-40.
PubMed
3) Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain : concepts, challenges, and compromises. Pain 2020 ; 161 : 1976-82.
 
4) 古江秀昌, 野口光一. 侵害受容性, 神経障害性, nociplasticな疼痛の区別. 田口敏彦, 飯田宏樹, 牛田享宏監修. 疼痛医学. 東京 : 医学書院 ; 2020. p.7-10.
 
5) Mercadante S. Malignant bone pain : pathophysiology and treatment. Pain 1997 ; 69 : 1-18.
PubMed
6) Zajaczkowska R, Kocot-Kepska M, Leppert W, et al. Bone pain in cancer patients : mechanisms and current treatment. Int J Mol Sci 2019 ; 20 : 6047.
 
7) Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006 ; 12 : 6243-9s.
 
8) Figura N, Smith J, Yu HM. Mechanisms of, and adjuvants for, bone pain. Hematol Oncol Clin North Am 2018 ; 32 : 447-58.
PubMed
9) Mantyh PW. The neurobiology of skeletal pain. Eur J Neurosci 2014 : 39 ; 508-19.
PubMed
10) Park SH, Eber MR, Widner DB, et al. Role of the bone microenvironment in the development of painful complications of skeletal metastases. Cancers (Basel) 2018 ; 10 : 141.
PubMed
11) Mantyh P. Bone cancer pain : causes, consequences, and therapeutic opportunities. Pain 2013 ; 154 Suppl 1 : S54-62.
 
12) Lozano-Ondoua AN, Symons-Liguori AM, Vanderah TW. Cancer-induced bone pain : mechanisms and models. Nurosci Lett 2013 ; 557 : 52-9.
 
13) Gerwin RD. Classification, epidemiology, and natural history of myofascial pain syndrome. Curr Pain Headache Rep 2001 ; 5 : 412-20.
PubMed
14) Kalichman L, Menahem I, Treger I. Myofascial component of cancer pain review. J Bodyw Mov Ther 2019 ; 23 : 311-5.
PubMed
15) Ceyhan GO, Michalski CW, Demir IE, et al. Pancreatic pain. Best Pract Res Clin Gastroenterol 2008 ; 22 : 31-44.
PubMed
16) Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain : an updated grading system for research and clinical practice. Pain 2016 ; 157 : 1599-606.
PubMed
17) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン改訂版作成ワーキンググループ編. 神経障害性疼痛の定義. 神経障害性疼痛薬物療法ガイドライン改訂第2版. 東京 : 真興交易医書出版部 ; 2016. p.18-9.
 
18) Baron R, Binder A, Wasner G. Neuropathic pain : diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010 ; 9 : 807-19.
PubMed
19) McKemy DD, Neuhausser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002 ; 416 : 52-8.
PubMed
20) Serra J, Sola R, Quiles C, et al. C-nociceptors sensitized to cold in a patient with small-fiber neuropathy and cold allodynia. Pain 2009 ; 147 : 46-53.
 
21) Price MP, McIlwrath SL, Xie J, et al. The DRASIC cation channel contributes to the detection of cutaneous touch and acid stimuli in mice. Neuron 2001 ; 32 : 1071-83.
 
22) Baron R, Schattschneider J, Binder A, et al. Relation between sympathetic vasoconstrictor activity and pain and hyperalgesia in complex regional pain syndromes : a case-control study. Lancet 2002 ; 359 : 1655-60.
PubMed
23) Woolf CJ, Thompson SWN. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation ; implications for the treatment of post-injury pain hypersensitivity states. Pain 1991 ; 44 : 293-9.
 
24) Cole JS, Patchell RA. Metastatic epidural spinal cord compression. Lancet Neurol 2008 ; 7 : 459-66.
PubMed
25) Warade AC, Jha AK, Pattankar S, et al. Radiation-induced brachial plexus neuropathy : a review. Neurol India 2019 ; 67 (Supplement) : S47-52.
PubMed
26) Brejt N, Berry J, Nisbet A, et al. Pelvic radiculopathies, lumbosacral plexopathies, and neuropathies in oncologic disease : a multidisciplinary approach to a diagnostic challenge. Cancer Imaging 2013 ; 13 : 591-601.
 
27) Aggarwal P, Zaveri JS, Goepfert RP, et al. Symptom burden associated with late lower cranial neuropathy in long-term oropharyngeal cancer survivors. JAMA Otolaryngol Head Neck Surg 2018 ; 144 : 1066-76.
PubMed
28) McDermott RS, Anderson PR, Greenberg RE, et al. Cranial nerve deficits in patients with metastatic prostate carcinoma : clinical features and treatment outcomes. Cancer 2004 ; 101 : 1639-43.
PubMed
29) Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004 ; 75 : 1135-40.
PubMed
30) Zis P, Paladini A, Piroli A, et al. Pain as a first manifestation of paraneoplastic neuropathies : a systematic review and meta-analysis. Pain Ther 2017 ; 6 : 143-51.
 
31) Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003 ; 349 : 1543-54.
PubMed
32) Antoine JC, Camdessanche JP. Paraneoplastic neuropathies. Curr Opin Neurol 2017 ; 30 : 513-20.
PubMed
33) Kanzawa-Lee GA, Knoerl R, Donohoe C, et al. Mechanisms, predictors, and challenges in assessing and managing painful chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 2019 ; 35 : 253-60.
PubMed
34) Yoon SY, Oh J. Neuropathic cancer pain : prevalence, pathophysiology, and management. Korean J Intern Med 2018 ; 33 : 1058-69.
PubMed
35) Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004 ; 96 : 1682-91.
PubMed
36) Griffith KA, Zhu S, Johantgen M, et al. Oxaliplatin-induced peripheral neuropathy and identification of unique severity groups in colorectal cancer. J Pain Symptom Manage 2017 ; 54 : 701-6.
PubMed
37) Madsen ML, Due H, Ejskjar N, et al. Aspects of vincristine-induced neuropathy in hematologic malignancies : a systematic review. Cancer Chemother Pharmacol 2019 ; 84 : 471-85.
PubMed
38) Li T, Timmins HC, Lazarus HM, et al. Peripheral neuropathy in hematologic malignancies-past, present and future. Blood Rev 2020 ; 43 : 100653.
PubMed
39) Humble SR, Varela N, Jayaweera A, et al. Chronic postsurgical pain and cancer : the catch of surviving the unsurvivable. Curr Opin Support Palliat Care 2018 ; 12 : 118-23.
PubMed
40) Masselin-Dubois A, Attal N, Fletcher D, et al. Are psychological predictors of chronic postsurgical pain dependent on the surgical model? A comparison of total knee arthroplasty and breast surgery for cancer. J Pain 2013 ; 14 : 854-64.
 
41) Schou Bredal I, Smeby NA, Ottesen S, et al. Chronic pain in breast cancer survivors : comparison of psychosocial, surgical, and medical characteristics between survivors with and without pain. J Pain Symptom Manage 2014 ; 48 : 852-62.
 
42) Astrup GL, Rustoen T, Miaskowski C, et al. Changes in and predictors of pain characteristics in patients with head and neck cancer undergoing radiotherapy. Pain 2015 ; 156 : 967-79.
PubMed
43) Jiang J, Li Y, Shen Q, et al. Effect of pregabalin on radiotherapy-related neuropathic pain in patients with head and neck cancer : a randomized controlled trial. J Clin Oncol 2019 ; 37 : 135-43.
 

II がん性疼痛に使用される薬物

P.18 掲載の参考文献
1) Derry S, Wiffen PJ, Moore RA, et al. Oral nonsteroidal anti-inflammatory drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev 2017 ; 7 : CD012638.
PubMed
2) Magee DJ, Jhanji S, Poulogiannis G, et al. Nonsteroidal anti-inflammatory drugs and pain in cancer patients : a systematic review and reappraisal of the evidence. Br J Anaesth 2019 ; 123 : e412-23.
PubMed
3) Eisenberg E, Berkey CS, Carr DB, et al. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain : a meta-analysis. J Clin Oncol 1994 ; 12 : 2756-65.
PubMed
4) Bjorkman R, Ullman A, Hedner J. Morphine-sparing effect of diclofenac in cancer pain. Eur J Clin Pharmacol 1993 ; 44 : 1-5.
PubMed
5) Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002 ; 62 : 625-31.
PubMed
6) Farooqui M, Li Y, Rogers T, et al. COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 2007 ; 97 : 1523-31.
PubMed
7) Sanchez-Covarrubias L, Slosky LM, Thompson BJ, et al. P-glycoprotein modulates morphine uptake into the CNS : a role for the non-steroidal anti-inflammatory drug diclofenac. PLoS One 2014 ; 9 : e88516.
PubMed
8) Sakamoto C, Sugano K, Ota S, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 2006 ; 62 : 765-72.
PubMed
9) Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications : a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012 ; 35 : 1127-46.
PubMed
10) Yibirin M, De Oliveira D, Valera R, et al. Adverse effects associated with proton pump inhibitor use. Cureus 2021 ; 13 : e12759.
PubMed
11) Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs : an update for clinicians : a scientific statement from the American Heart Association. Circulation 2007 ; 115 : 1634-42.
PubMed
12) Schneider V, Levesque LE, Zhang B, et al. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure : a population-based, nested case-control analysis. Am J Epidemol 2006 ; 164 : 881-9.
 
P.23 掲載の参考文献
1) Ishitsuka Y, Kondo Y, Kadowaki D. Toxicological property of acetaminophen : The dark side of a safe antipyretic/analgesic drug? Biol & Pharm Bull 2020 ; 43 : 195-206.
PubMed
2) Hogestatt ED, Jonsson BA, Ermund A, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 2005 ; 280 : 31405-12.
 
3) Lachiewicz PF. The role of intravenous acetaminophen in multimodal pain protocols for perioperative orthopedic patients. Orthopedics 2013 ; 36 (2 Suppl) : 15-9.
 
4) あゆみ製薬. カロナール(R) 錠200/カロナール(R) 錠300/カロナール(R) 錠500. 添付文書. 2021.
 
5) テルモ. アセリオ(R) 静注液1000 mg バッグ. 添付文書. 2021.
 
6) あゆみ製薬. カロナール(R) 坐剤100/カロナール(R) 坐剤200/カロナール(R) 坐剤400. 添付文書. 2021.
 
7) 日本緩和医療学会ガイドライン統括委員会編. がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020. p.58-9.
 
8) World Health Organization. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018.
PubMed
9) Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain : evidence-based recommendations from the EAPC. Lancet Oncol 2012 ; 13 : e58-68.
PubMed
10) Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients : ESMO Clinical Practice Guidelines. Ann Oncol 2018 ; 29 (Suppl 4) : iv166-91.
 
11) Swarm RA, Paice JA, Anghelescu DL, et al. Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Nat Compr Canc Netw 2019 ; 17 : 977-1007.
 
12) 山口重樹. 第3章 鎮痛薬の種類 1. 非オピオイド鎮痛薬 1. アセトアミノフェン. 山口重樹, 下山直人編. 症例で身につくがん疼痛治療薬-効果判定から薬の増減, 次の一手まで, 患者にあった処方がわかる. 東京 : 羊土社 ; 2014. p71-6.
 
13) 厚生労働省. ジェネリック医薬品への疑問に答えます～ジェネリック医薬品Q&A～. https://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000078998_3.pdf (accessed June 6, 2021)
 
P.31 掲載の参考文献
1) 世界保健機関編. 武田文和訳. がんの痛みからの解放-WHO方式がん疼痛治療法-. 第2版. 東京 : 金原出版 ; 1996.
 
2) 日本緩和医療学会ガイドライン総括委員会編. がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020.
 
3) 末永和之, 佐野隆信. 鎮痛補助薬 3) ステロイド. 綜合臨牀 2003 ; 52 : 2369-73.
Medical*Online
4) 浦部晶夫, 島田和幸, 川合眞一ほか編. 副腎皮質ステロイド. 今日の治療薬 2021 : 解説と便覧. 第43版. 東京 : 南江堂 ; 2021. p.269-76.
 
5) 池永昌之. がん悪液質症候群とコルチコステロイドによる症状緩和. 静脈経腸栄養 2008 ; 23 : 623-8.
 
6) 下条正子, 宮地幸隆. ステロイドホルモン (グルココルチコイド, ミネラロコルチコイド, アンドロゲン, エストロゲン). 日本臨牀 2003 ; 61 (増刊号6) : 234-7.
Medical*Online
7) 淀川キリスト教病院ホスピス編. コルチコステロイド. 緩和ケアマニュアル第5版. 大阪 : 最新医学社 ; 2007. p.227-34.
 
8) Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor : diagnosis and treatment. Ann Neurol 1978 ; 3 : 40-51.
PubMed
9) 飯田良司, 柏崎美保, 伊藤真介ほか. 神経因性疼痛を有するがん疼痛患者に対する鎮痛補助薬の鎮痛効果. ペインクリニック 2001 ; 22 : 212-8.
 
10) Portenoy RK. Adjuvant analgesics in cancer pain management. Doyle D, Hanks G, MacDonald N, editor. Oxford Textbook of Palliative Medicine. 2nd ed. New York : Oxford Medical Publication ; 1998. p.361-90.
 
11) Messer J, Reitman D, Sacks HS, et al. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983 ; 309 : 21-4.
PubMed
12) Hanks GW, Trueman T, Twycross RG. Corticsteroids in terminal cancer-a prospective analysis of current practice. Postgrad Med J 1983 ; 59 : 702-6.
 
13) 林瑤子, 名和秀起, 北村佳久ほか. 薬物相互作用 (29-ステロイドの薬物相互作用). 岡山医会誌 2014 ; 126 : 59-63.
 
P.35 掲載の参考文献
1) World Health Organization. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018.
PubMed
2) 日本緩和医療学会ガイドライン統括委員会編. がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020. p.60-1, p.123-4.
 
3) 日本緩和医療薬学会編. 緩和医療薬学. 東京 : 南江堂 ; 2013. p.45.
 
4) Bandieri E, Romero M, Ripamonti CI, et al. Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 2016 ; 34 : 436-42.
PubMed
5) 山口重樹, 白川賢宗, Taylor DR. D. オピオイド : 1 弱オピオイドコデイン/ジヒドロコデイン/トラマドール. 花岡一雄編. 誰にでも理解できる緩和ケアの実践書. 東京 : 克誠堂出版 ; 2015. p.55-64.
 
6) 慢性疼痛診療ガイドライン作成ワーキンググループ編. 慢性疼痛診療ガイドライン. 東京 : 真興交易医書出版部 ; 2021. p.67-8.
 
7) 田上恵太, 中川貴之. 第II章 症状緩和 2. がん疼痛F マネジメント. 日本緩和医療学会編. 専門家をめざす人のための緩和医療学. 改訂第2版. 東京 : 南江堂 ; 2019. p.68-81.
 
8) 徳山尚吾. 第VI章 オピオイド性鎮痛薬各論 4. コデイン (リン酸コデイン). 日本緩和医療薬学会編. 臨床緩和医療薬学. 東京 : 真興交易医書出版部 ; 2008. p.124-6.
 
9) Kondo I, Yonaha M, Okano K, et al. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population. Pharmacogenetics 1991 ; 1 : 161-4.
 
10) 日本ペインクリニック学会非がん性慢性疼痛に対するオピオイド鎮痛薬処方ガイドライン作成ワーキンググループ編. 非がん性慢性疼痛に対するオピオイド鎮痛薬処方ガイドライン 改訂第2版. 東京 : 真興交易医書出版部 ; 2017. p.78-81.
 
11) 岸岡史郎. 基礎編 2. オピオイドの分布と代謝. 並木昭義, 表圭一編. オピオイド. 東京 : 克誠堂出版 ; 2005. p.13-4.
 
12) 太田孝一. 臨床編 3. モルヒネ以外のオピオイド製剤とその特徴. 並木昭義, 表圭一編. オピオイド. 東京 : 克誠堂出版 ; 2005. p.82-3.
 
13) 武田薬品工業. コデインリン酸塩水和物「タケダ」原末, コデインリン酸塩散10%「タケダ」, コデインリン酸塩錠20 mg「タケダ」. 医薬品インタビューフォーム. 2019年7月改訂 (第10版).
 
14) 星茜. 6. 薬物療法 : 各論 3) コデインリン酸塩, トラマドール. ペインクリニック 2019 ; 40 (別冊秋) : S321-7.
Medical*Online
15) 岡本禎晃. 第3章 医療用麻薬の各薬剤における特徴. 第4章 医療用麻薬の剤形・投与方法別の特徴および使用方法. 茅根義和, 細谷 治編. 臨床医のくすり箱医療用麻薬. 東京 : 南山堂 ; 2011. p.61-3, p.75-8.
 
16) 日本麻酔科学会編. XI ペイン 3. オピオイド・オピオイド拮抗薬 コデインリン酸塩水和物. 麻酔薬および麻酔関連薬使用ガイドライン. 第3版. 2015. p.480-1.
 
17) 武田薬品工業. ジヒドロコデインリン酸塩「タケダ」原末, ジヒドロコデインリン酸塩散10%「タケダ」. 医薬品インタビューフォーム. 2019年7月改訂 (第9版).
 
18) Fallon MT, Cherny NI. Section 9 Common symptoms and disorders : pain. 9.4 Opioid therapy : optimizing analgesic outcomes. In : Cherny N, Fallon M, Kaasa S, et al, editors. Oxford textbook of palliative medicine. 5th ed. Oxford : Oxford University Press ; 2015. p.534-7.
 
P.43 掲載の参考文献
1) Benson GJ, Tranquilli WJ. Advantages and guidelines for using opioid agonist-antagonist analgesics. Vet Clin North Am Small Anim Pract 1992 ; 22 : 363-5.
PubMed
2) Dykstra LA, Preston KL, Bigelow GE. Discriminative stimulus and subjective effects of opioids with mu and kappa activity : data from laboratory animals and human subjects. Psychopharmacology (Berl) 1997 ; 130 : 14-27.
PubMed
3) Shu H, Hayashida M, Arita H, et al. Pentazocine-induced antinociception is mediated mainly by μ-opioid receptors and compromised by κ-opioid receptors in mice. J Pharmacol Exp Ther 2011 ; 338 : 579-87.
 
4) Levine JD, Gordon NC. Synergism between the analgesic actions of morphine and pentazocine. Pain 1988 ; 33 : 369-72.
PubMed
5) Hamura H, Yoshida M, Shimizu K, et al. Antinociceptive effect of the combination of pentazocine with morphine in the tail-immersion and scald-pain tests in rats. Jpn J Pharmacol 2000 ; 83 : 286-92.
PubMed
6) Shu H, Wang Z, Ye F, et al. High-dose pentazocine antagonizes the antinociception induced by high-dose morphine. Life Sci 2015 ; 130 : 1-6.
 
7) van Niel JC, Schneider J, Tzschentke TM. Efficacy of full μ-opioid receptor agonists is not impaired by concomitant buprenorphine or mixed opioid agonists/antagonists-preclinical and clinical evidence. Drug Res (Stuttg) 2016 ; 66 : 562-70.
 
8) 井手康雄. II. オピオイド 2. 拮抗性鎮痛薬 (ペンタゾシン, ブプレノルフィン). 麻酔 2022 ; 71 : 18-22.
Medical*Online
9) 井手康雄. D. 各種オピオイド適応・投与時の注意点 7. ペンタゾシン. ペインクリニック 2012 ; 33 (別冊秋) : S459-64.
 
10) Hanks GW. The clinical usefulness of agonist-antagonistic opioid analgesics in chronic pain. Drug Alcohol Depend 1987 ; 20 : 339-46.
PubMed
11) Naing C, Yeoh PN, Aung K. A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain. Springerplus 2014 ; 3 : 87.
PubMed
12) Kamei J, Sodeyama M, Tsuda M, et al. Antinociceptive effect of buprenorphine in μ1-opioid receptor deficient CXBK mice. Life Sci 1997 ; 60 : PL333-7.
 
13) Leander JD. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 1987 ; 26 : 1445-7.
PubMed
14) Walker EA, Zernig G, Woods JH. Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 1995 ; 273 : 1345-52.
PubMed
15) Christoph T, Kogel B, Schiene K, et al. Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 2005 ; 507 : 87-98.
PubMed
16) Lutfy K, Cowan A. Buprenorphine : a unique drug with complex pharmacology. Curr Neuropharmacol 2004 ; 2 : 395-402.
PubMed
17) Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006 ; 96 : 627-32.
 
18) Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract 2010 ; 10 : 428-50.
PubMed
19) Prommer E. Buprenorphine for cancer pain : is it ready for prime time? Am J Hosp Palliat Care 2015 ; 32 : 881-9.
PubMed
20) Davis MP, Pasternak G, Behm B. Treating chronic pain : an overview of clinical studies centered on the buprenorphine option. Drugs 2018 ; 78 : 1211-28.
PubMed
21) Hans G, Robert D. Transdermal buprenorphine-a critical appraisal of its role in pain management. J Pain Res 2009 ; 2 : 117-34.
PubMed
22) Ahn JS, Lin J, Ogawa S, et al. Transdermal buprenorphine and fentanyl patches in cancer pain : a network systematic review. J Pain Res 2017 ; 10 : 1963-72.
PubMed
23) Likar R. Transdermal buprenorphine in the management of persistent pain-safety aspects. Ther Clin Risk Manag 2006 ; 2 : 115-25.
PubMed
24) Mercadante S, Porzio G, Fulfaro F, et al. Switching from transdermal drugs : an observational "N of 1" study of fentanyl and buprenorphine. J Pain Symptom Manage 2007 ; 34 : 532-8.
PubMed
25) Mercadante M, Casuccio A, Tirelli W, et al. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Support Care Cancer 2009 ; 17 : 715-8.
 
26) Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain : results of a retrospective cohort study. Clin Ther 2005 ; 27 : 225-37.
PubMed
27) Nasser AF, Heidbreder C, Liu Y, et al. Pharmacokinetics of sublingual buprenorphine and naloxone in subjects with mild to severe hepatic impairment (child-pugh classes A, B, and C), in hepatitis C virus-seropositive subjects, and in healthy volunteers. Clin Pharmacokinet 2015 ; 54 : 837-49.
 
28) Filitz J, Griessinger N, Sittl R, et al. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 2006 ; 10 : 743-8.
PubMed
29) Hand CW, Sear JW, Uppington J, et al. Buprenorphine disposition in patients with renal impairment : single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990 ; 64 : 276-82.
PubMed
30) Likar R, Vadlau EM, Breschan C, et al. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Clin J Pain 2008 ; 24 : 536-43.
PubMed
P.53 掲載の参考文献
1) 田端守. モルヒネの発見者ザーチュルナーの史蹟. 薬史学誌 1998 ; 33 : 9-17.
 
2) World Health Organization. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018.
PubMed
3) 平林高暢, 間宮敬子. 特集 : 麻酔科医による緩和医療の最近の知見-オピオイドをどう使いこなすか. Anet 2020 ; 24 : 3-6.
 
4) 山代亜紀子. 特集 : 意外に知られていないモルヒネによる痛み治療の問題点と実際 (1) がん疼痛緩和におけるモルヒネの役割-作用機序と使用法, 副作用対策. 医事新報 2019 ; 4956 : 18-23.
 
5) 日本緩和医療学会ガイドライン統括委員会編. がん疼痛の薬物療法に関するガイドライン 2020 年版. 東京 : 金原出版 ; 2020. p.60-142.
 
6) 佐伯茂. コデイン, モルヒネ. 細川豊史編. 慢性疼痛治療-現場で役立つオピオイド鎮痛薬の必須知識. 大阪 : 医薬ジャーナル社 ; 2015. p.44-52.
 
7) Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide-a potent antagonist of morphine analgesia. Life Sci 1990 ; 47 : 579-85.
PubMed
8) 田上恵太, 中川貴之. がん疼痛. 日本緩和医療学会編. 専門家をめざす人のための緩和医療学. 改訂第2版. 東京 : 南江堂 ; 2019. p.60-88.
 
9) 日本緩和医療学会緩和医療ガイドライン委員会編. がん患者の呼吸器症状の緩和に関するガイドライン 2016年版. 東京 : 金原出版 ; 2016. p.66-103.
 
10) Tassinari D, Sartori S, Tamburini E, et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine : a meta-analysis and systematic review of the literature. J Palliat Med 2008 ; 11 : 492-501.
 
11) Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain : evidence-based recommendations from the EAPC. Lancet Oncol 2012 ; 13 : e58-68.
PubMed
12) Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing "best practices" for opioid rotation : conclusions of an expert panel. J Pain Symptom Manage 2009 ; 38 : 418-25.
 
13) Gomutbutra P, O'Riordan DL, Pantilat SZ. Management of moderate-to-severe dyspnea in hospitalized patients receiving palliative care. J Pain Symptom Manage 2013 ; 45 : 885-91.
PubMed
14) World Health Organization (WHO). WHO Guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. 2012.
PubMed
15) 多田羅竜平. 小児. 日本緩和医療学会編. 専門家をめざす人のための緩和医療学. 改訂第2版. 東京 : 南江堂 ; 2019. p.330-7.
 
16) 間宮敬子. 妊産婦への投与法. 細川豊史編. 慢性疼痛治療-現場で役立つオピオイド鎮痛薬の必須知識. 大阪 : 医薬ジャーナル社 ; 2015. p.184-7.
 
17) 平田純生, 古久保拓編著. 透析患者への投薬ガイドブック : 慢性腎臓病 (CKD) の薬物治療. 改訂3版. 東京 : じほう ; 2017. p.1048-50.
 
18) Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients : ESMO Clinical Practice Guidelines. Ann Oncol 2018 ; 29 : iv166-91.
PubMed
P.57 掲載の参考文献
1) Yoburn BC, Shah S, Chan K, et al. Supersensitivity to opioid analgesics following chronic opioid antagonist treatment : relationship to receptor selectivity. Pharmacol Biochem Behav 1995 ; 51 : 535-9.
PubMed
2) Kalso E, Vainio A, Mattila MJ, et al. Morphine and oxycodone in the management of cancer pain : plasma levels determined by chemical and radioreceptor assays. Pharmacol Toxicol 1990 ; 67 : 322-8.
PubMed
3) Ross FB, Smith MT. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997 ; 73 : 151-7.
PubMed
4) Nielsen CK, Ross FB, Lotfipour S, et al. Oxycodone and morphine have distinctly different pharmacological profiles : radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007 ; 132 : 289-300.
PubMed
5) Leow KP, Smith MT, Williams B, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992 ; 52 : 487-95.
PubMed
6) Poyhia R, Seppala T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992 ; 33 : 617-21.
PubMed
7) Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004 ; 32 : 447-54.
PubMed
8) Lemberg KK, Siiskonen AO, Kontinen VK, et al. Pharmacological characterization of noroxymorphone as a new opioid for spinal analgesia. Anesth Analg 2008 ; 106 : 463-70.
PubMed
9) 木澤義之, 塩川満, 鈴木勉監訳. WHOガイドライン成人・青年における薬物療法・放射線治療によるがん疼痛マネジメント. 東京 : 金原出版 ; 2021.
 
10) 日本緩和医療学会ガイドライン統括委員会編. がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020.
 
11) 日本ペインクリニック学会非がん性慢性疼痛に対するオピオイド鎮痛薬処方ガイドライン作成ワーキンググループ編. 非がん性慢性疼痛に対するオピオイド鎮痛薬処方ガイドライン 改訂第2版. 東京 : 真興交易医書出版部 ; 2017.
 
12) Narabayashi M, Saijo Y, Takenoshita S, et al. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects : an open-label trial. Jpn J Clin Oncol 2008 ; 38 : 296-304.
PubMed
13) Lee MA, Leng ME, Cooper RM. Measurements of plasma oxycodone, noroxycodone and oxymorphone levels in a patient with bilateral nephrectomy who is undergoing haemodialysis. Palliat Med 2005 ; 19 : 259-60.
 
14) 松田陽一. II. オピオイド 4. 強オピオイド (オキシコドン). 麻酔 2022 ; 71 : 32-6.
Medical*Online
15) 塩野義製薬. オキファスト(R) 注インタビューフォーム. 2012.
 
P.70 掲載の参考文献
1) Stanley TH. The fentanyl story. J Pain 2014 ; 15 : 1215-26.
 
2) Stanley TH. Fentanyl. J Pain Symptom Manage 2005 ; 29 (5 Suppl) : S67-71.
 
3) Yeadon M, Kitchen I. Comparative binding of mu and delta selective ligands in whole brain and pons/medulla homogenates from rat : affinity profiles of fentanyl derivatives. Neuropharmacology 1988 ; 27 : 345-8.
PubMed
4) Maguire P, Tsai N, Kamal J, et al. Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. Eur J Pharmacol 1992 ; 213 : 219-25.
PubMed
5) Raynor K, Kong H, Chen Y, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol 1994 ; 45 : 330-4.
PubMed
6) Marquardt KA, Tharratt RS, Musallam NA. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother 1995 ; 29 : 969-71.
 
7) 高折修二, 福田英臣, 赤池昭紀ほか監訳. グッドマン・ギルマン薬理書 : 薬物治療の基礎と臨床 (上巻). 第11版. 東京 : 廣川書店 ; 2007. p.669-728.
 
8) Bernards C. Clinical implications of physicochemical properties of opioids. Stein C, editor. Opioids in Pain Control : Basic and clinical aspects. Cambridge : Cambridge University Press ; 1998. p166-87.
 
9) Megens AA, Artois K, Vermeire J, et al. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 1998 ; 15 : 253-7.
PubMed
10) Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy : a comparative study. South Med J 2004 ; 97 : 129-34.
PubMed
11) Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain : preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997 ; 13 : 254-61.
 
12) Herz A, Teschemacher H. Activities and sites of antinociceptive action of morphine like analgesics and kinetics of distribution following intravenous, intracerebral and intraventricular application. In : Simmonds A, editor. Advances in drug research. London : Academic ; 1971. p.79-119.
 
13) Mayes S, Ferrone M. Fentanyl HCl patient-controlled iontophoretic transdermal system for the management of acute postoperative pain. Ann Pharmacother 2006 ; 40 : 2178-86.
PubMed
14) 日本緩和医療学会ガイドライン統括委員会編. がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020.
 
15) Gutstein HB, Akil H.Opioid analgesics. In : Hardman JG, Limbird LE, editor. Goodman & Gilman's the pharmacological basis of therapeutics.10th ed. New York : McGraw-Hill ; 2001. p.1957.
 
16) Tassinari D, Drudi F, Rosati M, et al. Transdermal opioids as front line treatment of moderate to severe cancer pain : a systemic review. Palliat Med 2011 ; 25 : 478-87.
PubMed
17) Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain : an observational study of 1000 European oncology patients. J Pain Symptom Manage 2013 ; 46 : 619-28.
PubMed
18) Zeppetella G. Opioids for cancer breakthrough pain : a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008 ; 35 : 563-7.
PubMed
19) Deandrea S, Corli O, Consonni D, et al. Prevalence of breakthrough cancer pain : a systematic review and a pooled analysis of published literature. J Pain Symptom Manage 2014 ; 47 : 57-76.
 
20) Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev 2013 ; 10 : CD004311.
PubMed
21) Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain : evidence-based recommendations from the EAPC. Lancet Oncol 2012 ; 13 : e58-68.
PubMed
22) Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain : ESMO Clinical Practice Guidelines. Ann Oncol 2012 ; 23 Suppl 7 : vii139-54.
 
23) National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology : Adult Cancer Pain. version 2. 2016.
 
24) King S, Forbes K, Hanks GW, et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment : a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011 ; 25 : 525-52.
 
25) 厚生労働省科学研究費補助金平成27年度日本医療開発機構腎疾患実用化研究事業「慢性腎臓病の進行を促進する薬剤等による腎障害の早期診断法と治療法の開発」薬剤性腎障害の診療ガイドライン作成委員会. 薬剤性腎障害診療ガイドライン 2016. 日腎会誌 2016 ; 58 : 477-555.
 
26) Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain : preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997 ; 13 : 254-61.
 
27) Marquardt KA, Tharratt RS, Musallam NA. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother 1995 ; 29 : 969-71.
 
28) Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain : recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009 ; 13 : 331-8.
PubMed
29) Cherny N, Fallon M, Kaasa S, et al. Oxford Textbook of Palliative Medicine. 5th ed. Oxford : Oxford University Press ; 2015. p.1004-12.
 
30) Roda G, Faggiani F, Bolchi C, et al. Ten years of fentanyl-like drugs : a technical-analytical review. Anal Sci 2019 ; 35 : 479-91.
PubMed
31) Narita M, Nakamura A, Ozaki M, et al. Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice : evidence for less sensitivity to morphine. Neuropsychopharmacology 2008 ; 33 : 1097-112.
 
32) Imai S, Narita M, Hashimoto S, et al. Differences in tolerance to anti-hyperalgesic effects between chronic treatment with morphine and fentanyl under a state of pain. Jpn J Neuropsychopharmacol 2006 ; 26 : 183-92.
 
P.83 掲載の参考文献
1) Tzschentke TM, Christoph T, Kogel B, et al. (-) - (1R, 2R) -3 - (3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol hydrochloride (tapentadol HCl) : a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007 ; 323 : 265-76.
 
2) Raffa RB, Buschmann H, Christoph T, et al. Mechanistic and functional differentiation of tapentadol and tramadol. Expert Opin Pharmacother 2012 ; 13 : 1437-49.
PubMed
3) 中川貴之. トラマドールおよび新規オピオイド系鎮痛薬タペンタドールの鎮痛作用機序とその比較. 日緩和医療薬誌 2013 ; 6 : 11-22.
 
4) Tzschentke TM, Christoph T, Kogel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia : the case of tapentadol. CNS Drugs 2014 ; 28 : 319-29.
PubMed
5) Anand P, Dickenson A, Finco G, et al. Novel insights on the management of pain : highlights from the'Science of Relief'meeting. Pain Manag 2019 ; 9 : 521-33.
PubMed
6) Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992 ; 260 : 275-85.
 
7) Frink MC, Hennies HH, Englberger W, et al. Influence of tramadol on neurotransmitter systems of the rat brain. Arzneimittelforschung 1996 ; 46 : 1029-36.
PubMed
8) Schroder W, Vry JD, Tzschentke TM, et al. Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur J Pain 2010 ; 14 : 814-21.
PubMed
9) Nossman VE, Ramadhyani U, Kadowitz PJ, et al. Advances in perioperative pain management : use of medications with dual analgesic mechanisms, tramadol & tapentadol. Anesthesiology Clin 2010 ; 28 : 647-66.
 
10) Pettersen VL, Zapata-Sudo G, Raimundo JM, et al. The synergistic interaction between morphine and maprotiline after intrathecal injection in rats. Anesth Analg 2009 ; 109 : 1312-7.
PubMed
11) Romualdi P, Grilli M, Canonico PL, et al. Pharmacological rationale for tapentadol therapy : a review of new evidence. J Pain Res 2019 ; 12 : 1513-20.
PubMed
12) 佐藤哲観. II. オピオイド 6. 強オピオイド (タペンタドール). 麻酔 2022 ; 71 : 46-51.
Medical*Online
13) Imanaka K, Tominaga Y, Etropolski M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin 2013 ; 29 : 1399-409.
PubMed
14) Imanaka K, Tominaga Y, Etropolski M, et al. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clin Drug Investig 2014 ; 34 : 501-11.
PubMed
15) Kress HG, Koch ED, Kosturski H, et al. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician 2014 ; 17 : 329-43.
PubMed
16) Etropolski M, Kuperwasser B, Flugel M, et al. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management : pooled analysis of randomized controlled trials. Adv Ther 2014 ; 31 : 604-20.
PubMed
17) Schikowski A, Krings D, Schwenke K. Tapentadol prolonged release for severe chronic cancer-related pain : effectiveness, tolerability, and influence on quality of life of the patients. J Pain Res 2014 ; 8 : 1-8.
 
18) Mercadante S, Porzio G, Aielli F, et al. Opioid switching from and to tapentadol extended release in cancer pain patients : conversion ratio with other opioids. Curr Med Res Opin 2013 ; 29 : 661-6.
PubMed
19) Imanaka K, Tominaga Y, Etropolski M, et al. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clin Drug Investig 2014 ; 34 : 501-11.
PubMed
20) Raffa RB, Elling C, Tzschentke TM. Does 'strong analgesic' equal 'strong opioid'? Tapentadol and the concept of 'μ-load'. Adv Ther 2018 ; 35 : 1471-84.
 
21) Polati E, Canonico PL, Schweiger V, et al. Tapentadol : an overview of the safety profile. J Pain Res 2019 ; 12 : 1569-76.
PubMed
22) Dart RC, Cicero TJ, Surratt HL, et al. Assessment of the abuse of tapentadol immediate release : the first 24 months. J Opioid Manag 2012 ; 8 : 395-402.
PubMed
23) Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential : a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med 2015 ; 16 : 119-30.
PubMed
24) 金島正幸, 余宮きのみ. タペンタドールと選択的セロトニン再取り込み阻害薬の併用でセロトニン症候群を発症した1例. Palliat Care Res 2019 ; 14 : 203-7.
 
25) Howard RF, Radic T, Sohns M, et al. Tapentadol prolonged release for long-term treatment of pain in children. J Pain Res 2020 ; 13 : 3157-70.
 
※ 大坂巌, 佐藤哲観. タペンタドールが変えるがん疼痛治療-ケースで学ぶ鎮痛薬の選択法. 東京 : 医学と看護社 ; 2016. p.4-79.
 
P.93 掲載の参考文献
1) 余宮きのみ. ヒドロモルフォン. がん疼痛緩和の薬がわかる本. 第3版. 東京 : 医学書院 ; 2019. p.130-7.
 
2) Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain : evidence-based recommendations from the EAPC. Lancet Oncol 2012 ; 13 : e58-68.
PubMed
3) Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients : ESMO Clinical Practice Guidelines. Ann Oncol 2018 ; 29 : iv166-91.
PubMed
4) National Cpmprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN GuidelinesR) : Adult cancer pain. ver 1. 2020.
 
5) Bao YJ, Hou W, Kong XY, et al. Hydromorphone for cancer pain. Cochrane Database Syst Rev 2016 ; 10 : CD011108.
PubMed
6) 日本緩和医療学会ガイドライン統括委員会編. がん疼痛のある, 高度腎機能障害患者に対して, 特定のオピオイドの投与は推奨されるか? がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020. p.153-5.
 
7) 日本緩和医療学会編. オピオイド. がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020. p.53-66.
 
8) Lee KA, Ganta N, Horton JR, et al. Evidence for neurotoxicity due to morphine or hydromorphone use in renal impairment : a systematic review. J Palliat Med 2016 ; 19 : 1179-87.
PubMed
9) Durnin C, Hind ID, Ghani SP, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Proc West Pharmacol Soc 2001 ; 44 : 83-4.
PubMed
10) Kloke M, Cherny N, ESMO Guidelines Committee. Treatment of dyspnoea in advanced cancer patients : ESMO Clinical Practice Guidelines. Ann Oncol 2015 ; 26 Suppl 5 : v169-73.
 
11) 余宮きのみ, 深澤義輝, 太田池恵ほか. II. オピオイド 7. 強オピオイド (ヒドロモルフォン). 麻酔 2022 ; 71 : 52-9.
Medical*Online
12) 日本緩和医療学会ガイドライン統括委員会編. オピオイドが原因で, 悪心・嘔吐のあるがん患者に対して, 制吐薬の投与は推奨されるか? がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020. p.146-8.
 
13) 日本緩和医療学会ガイドライン統括委員会編. がん疼痛のある患者に対して, より早く鎮痛するために, オピオイドを持続静注または持続皮下注で投与することは推奨されるか? がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020. p.158-9.
 
14) 余宮きのみ. ここが知りたかった緩和ケア. 改訂第2版. 東京 : 南江堂 ; 2019.
 
15) 第一三共. ナルサス(R) 錠2 mg/ナルサス(R) 錠6 mg/ナルサス(R) 錠12 mg/ナルサス(R) 錠24 mg. 添付文書. 2021年9月改訂 (第3版).
 
16) 余宮きのみ. ヒドロモルフォンを使用する際の換算比の考え方. 緩和ケア 2020 ; 30 : 393-5.
 
17) Wirz S, Wartenberg HC, Elsen C, et al. Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone : a prospective clinical trial. Clin J Pain 2006 ; 22 : 770-5.
PubMed
18) Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001 ; 15 : 26-34.
PubMed
19) Oldenmenger WH, Lieverse PJ, Janssen PJ, et al. Efficacy of opioid rotation to continuous parenteral hydromorphone in advanced cancer patients failing on other opioids. Support Care Cancer 2012 ; 20 : 1639-47.
PubMed
20) Manfredi PL, Borsook D, Chandler SW, et al. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone : clinical observations. Pain 1997 ; 70 : 99-101.
PubMed
21) Ishihara M, Ikesue H, Matsunaga H, et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain 2012 ; 28 : 373-81.
PubMed
22) Kanbayashi Y, Hosokawa T. Predictive factors for nausea or vomiting in patients with cancer who receive oral oxycodone for the first time : is prophylactic medication for prevention of opioidinduced nausea or vomiting necessary? J Palliat Med 2014 ; 17 : 683-7.
 
23) 久米初枝, 宮崎雅之, 加藤博史ほか. オキシコドン誘発悪心・嘔吐に対する予防的制吐薬の使用状況とその効果. 日緩和医療薬誌 2016 ; 9 : 75-80.
 
24) 山田正実, 松村千佳子, 地丸裕美ほか. オピオイド鎮痛薬導入時の悪心・嘔吐の予測因子の探索と化学療法の影響. Palliat Care Res 2020 ; 15 : 213-20.
 
25) King S, Forbes K, Hanks GW, et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment : a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011 ; 25 : 525-52.
 
26) Sande TA, Laird BJ, Fallon MT. The use of opioids in cancer patients with renal impairment-a systematic review. Support Care Cancer 2017 ; 25 : 661-75.
PubMed
27) Durnin C, Hind ID, Wickens MM, et al. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with renal impairment. Proc West Pharmacol Soc 2001 ; 44 : 81-2.
PubMed
28) Schmid CL, Kennedy NM, Ross NC, et al. Bias factor and therapeutic window correlate to predict safer opioid analgesics. Cell 2017 ; 171 : 1165-75. e13.
 
29) 吉田小莉, 濱田祐輔, 葛巻直子ほか. 鎮痛薬研究の最近の進歩. 臨床と研究 2020 ; 97 : 217-22.
Medical*Online
P.107 掲載の参考文献
1) メサペイン(R) 錠安全性評価委員会. メサペイン(R) 錠5 mg/同10 mg 適正使用ガイド. 2021年3月改訂 (第5版).
 
2) Schumacher MA, Basbaum AI, Naidu RK. Opioid agonists & antagonists. In : Katzung BG, Vanderah TW, editors. Basic & clinical pharmacology. 15th ed. New York : McGraw Hill ; 2021. p.573-95.
 
3) Fitzgibbon D. Cancer pain : principles of management and pharmacotherapy. In : Ballantyne JC, Fishman SM, Rathmell JP, editors. Bonica's management of pain. 5th ed. Philadelphia : Wolters Kluwer ; 2019. p.676-710.
 
4) Payte JT. A brief history of methadone in the treatment of opioid dependence : a personal perspective. J Psychoactive Drugs 1991 ; 23 : 103-7.
PubMed
5) Institute of Medicine (US) Committee on Federal Regulation of Methadone Treatment. Rettig RA, Yarmolinsky A, editors. Federal regulation of methadone treatment. Washington (DC) : National Academies Press ; 1995.
 
6) Prescott F, Ransom SG. Amidone (miadone) as an obstetric analgesic : trial in 62 cases. Lancet 1947 ; 2 : 501-3.
PubMed
7) World Health Organization. Cancer pain relief. 1986. http://apps.who.int/iris/bitstream/handle/10665/43944/9241561009_eng.pdf
 
8) 第166回国会参議院厚生労働委員会 第28号 平成19年6月12日. 会議録. https://kokkai.ndl.go.jp/simple/txt/116614260X02820070612/138,139,140,141
 
9) 関根龍一. メサドンの適応と臨床使用における要点. ペインクリニック 2013 ; 34 : 1489-502.
Medical*Online
10) Rudd RA, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths-United States, 2010-2015. MMWR Morb Mortal Wkly Rep 2016 ; 65 : 1445-52.
PubMed
11) Gourley GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain 1986 ; 25 : 297-312.
 
12) Bruera E, Sweeney C. Methadone use in cancer patients with pain : a review. J Palliat Med 2002 ; 5 : 127-38.
 
13) Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995 ; 56 : PL45-50.
PubMed
14) Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain : a review. Pain 1993 ; 52 : 137-47.
PubMed
15) Codd EE, Shank RP, Schupsky JJ, et al. Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics : structural determinants and role in antinociception. J Pharmacol Exp Ther 1995 ; 274 : 1263-70.
PubMed
16) Sotgiu ML, Valente M, Storchi R, et al. Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and μ-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res 2009 ; 60 : 284-90.
 
17) Gagnon B, Almahrezi A, Schreier G. Methadone in the treatment of neuropathic pain. Pain Res Manag 2003 ; 8 : 149-54.
PubMed
18) Haumann J, Geurts JW, van Kuijk SM, et al. Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer. Eur J Cancer 2016 ; 65 : 121-9.
PubMed
19) Garrido MJ, Troconiz IF. Methadone : a review of its pharmacokinetic/pharmacodynamic properties. J Pharmacol Toxicol Methods 1999 ; 42 : 61-6.
PubMed
20) Bruera E, Palmer JL, Bosnjak S, et al. Methadone versus morphine as a first-line strong opioid for cancer pain : a randomized, double-blind study. J Clin Oncol 2004 ; 22 : 185-92.
PubMed
21) シオノギ製薬ホームページ. 医療関係者向け情報. 医薬品インタビューフォーム. 癌疼痛治療剤メサドン塩酸塩錠. 2020年5月改訂 (第7版).
 
22) 北原雅樹. メサドンの米国での使用経験-正体見たり枯れ尾花-. ペインクリニック 2013 ; 34 : 1511-9.
Medical*Online
23) Wirz S, Klaschik E. Management of constipation in palliative care patients undergoing opioid therapy : is polyethylene glycol an option? Am J Hosp Palliat Care 2005 ; 22 : 375-81.
PubMed
24) Venegas G, Ripamonti C, Sbanotto A, et al. Side effects of morphine administration in cancer patients. Cancer Nurs 1998 ; 21 : 289-97.
 
25) Mercadante S, Bruera E. Opioid switching in cancer pain : from the beginning to nowadays. Crit Rev Oncol Hematol 2016 ; 99 : 241-8.
PubMed
26) Parsons HA, de la Cruz M, El Osta B, et al. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010 ; 116 : 520-8.
PubMed
27) McPherson ML, Walker KA, Davis MP, et al. Safe and appropriate use of methadone in hospice and palliative care : expert consensus white paper. J Pain Symptom Manage 2019 ; 57 : 635-45.e4.
 
28) Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety : a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 2014 ; 15 : 321-37.
PubMed
29) Nicholson AB, Watson GR, Derry S, et al. Methadone for cancer pain. Cochrane Database Syst Rev 2017 ; 2 : CD003971.
PubMed
30) McNicol ED, Ferguson MC, Schumann R. Methadone for neuropathic pain in adults. Cochrane Database Syst Rev 2017 ; 5 : CD012499.
PubMed
31) Haroutiunian S, McNicol ED, Lipman AG. Methadone for chronic non-cancer pain in adults. Cochrane Database Syst Rev 2012 ; 11 : CD008025.
PubMed
32) Mathew P, Storey P. Subcutaneous methadone in terminally ill patients : manageable local toxicity. J Pain Symptom Manage 1999 ; 18 : 49-52.
PubMed
33) Shir Y, Rosen G, Zeldin A, et al. Methadone is safe for treating hospitalized patients with severe pain. Can J Anaesth 2001 ; 48 : 1109-13.
PubMed
34) Jacobson L, Chabal C, Brody MC, et al. Intrathecal methadone : a dose-response study and comparison with intrathecal morphine 0.5 mg. Pain 1990 ; 43 : 141-8.
 
35) Hurley RW, Kent ML, Wu CL. Acute pain in adults. In : Ballantyne JC, Fishman SM, Rathmell JP, editors. Bonica's management of pain. 5th ed. Philadelphia : Wolters Kluwer ; 2019. p.826-49.
 
36) Kung CP, Sil BC, Hadgraft J, et al. Preparation, characterization and dermal delivery of methadone. Pharmaceutics 2019 ; 11 : 509.
PubMed
37) Murphy GS, Szokol JW. Intraoperative methadone in surgical patients : a review of clinical investigations. Anesthesiology 2019 ; 131 : 678-92.
PubMed
38) 稲川慎哉, 澤田幸一郎, 大島正寛ほか. 胃瘻からメサドンの投与を行い在宅緩和ケアが可能となった頭頚部癌の1例. Palliat Care Res 2018 ; 13 Supple : S341.
 
39) 小島佑太, 梶原徹, 小川洋司. メサドン錠を簡易懸濁法にて胃瘻より投与した1例. メサドン錠を簡易懸濁法にて胃瘻より投与した1例. 日本緩和医療薬学会年会プログラム・要旨集 2015 ; 9 : 199.
 
40) McLean S, Twomey F. Methods of rotation from another strong opioid to methadone for the management of cancer pain : a systematic review of the available evidence. J Pain Symptom Manage 2015 ; 50 : 248-59.
PubMed
41) Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing "best practices" for opioid rotation : conclusions of an expert panel. J Pain Symptom Manage 2009 ; 38 : 418-25.
 
42) Moksnes K, Dale O, Rosland JH, et al. How to switch from morphine or oxycodone to methadone in cancer patient ? a randomised clinical phase II trial. Eur J Cancer 2011 ; 47 : 2463-70.
 
43) Bruera E, Watanabe S, Fainsinger RL, et al. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain 1995 ; 62 : 141-6.
PubMed
44) Mercadante S. Switching methadone : a 10-year experience of 345 patients in an acute palliative care unit. Pain Med 2012 ; 13 : 399-404.
 
45) National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Version 2. 2021.
 
46) Emanuel LL, Ferris FD, von Gunten CF, et al. Module 2 : Cancer pain management. EPEC-O : Education in Palliative and End-of-life Care-Oncology. Participant's handbook. 2005.
 
47) Department of Veterans Affairs, Department of Defense. VA/DoD clinical practice guideline for opioid therapy for chronic pain. 2017.
PubMed
48) Flory JH, Wiesenthal AC, Thaler HT, et al. Methadone use and the risk of hypoglycemia for inpatients with cancer pain. J Pain Symptom Manage 2016 ; 51 : 79-87.
PubMed
49) World Health Organization. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018. https://apps.who.int/iris/bitstream/handle/10665/279700/9789241550390-eng.pdf
 
P.115 掲載の参考文献
1) 星野恵津夫, 井上美貴, 網谷真理恵ほか. 漢方医学的視点からみたがん患者が呈する基本的病態. 北島政樹監修. 今津嘉宏編. がん漢方. 東京 : 南山堂 ; 2012. p.26-35.
 
2) 恵紙英昭, 佐野智美, 八木実ほか. 緩和ケアにおける氷六君子湯 (iced rikkunshito) の役割. 痛みと漢方 2010 ; 20 : 20-9.
 
3) 間宮敬子. 16. がんの痛みと漢方. ペインクリニック 2017 ; 38 (別冊秋) : S417-24.
Medical*Online
4) 大道雅英. ブシ末 (修治ブシ末N(R)) の併用がオピオイドの劇的減量に大きく貢献したと考えられた難治性がん性疼痛の1例. 緩和ケア 2008 ; 18 : 255-60.
 
5) 川原玲子, 小山佐和子, 吉岡亮ほか. がん患者の状態・症状に合わせた漢方薬投与の実践. 薬局 2013 ; 64 : 2847-53.
 
6) 日高隆雄. 漢方薬の最新研究 婦人科癌と芍薬甘草湯 : パクリタキセル誘発疼痛マウスモデルに対する芍薬甘草湯の基礎的検討. 漢方医学 2010 ; 34 : 24-5.
 

III オピオイド

P.134 掲載の参考文献
1) Shimoyama N, Shimoyama M, Elliot KJ, et al. d-Methadone is antinociceptive in the rat formalin test. J Pharmacol Exp Ther 1997 ; 283 : 648-52.
 
2) Taylor DR. Managing Cancer Breakthrough Pain-Pocket Books for Cancer Supportive Care. New York : Springer Healthcare ; 2013.
 
3) Grissinger M. Keeping patients safe from methadone overdoses. P T 2011 ; 36 : 462-6.
PubMed
4) Portenoy RK, Hagen NA. Breakthrough pain : definition, prevalence and characteristics. Pain 1990 ; 41 : 273-81.
PubMed
5) Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing"best practices"for opioid rotation : conclusions of an expert panel. J Pain Symptom Manage 2009 ; 38 : 418-25.
 
6) Shimoyama N, Gomyo I, Teramoto O, et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain. Jpn J Clin Oncol 2015 ; 45 : 189-96.
PubMed
7) Shimoyama N, Gomyo I, Katakami N, et al. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients : a multicenter, randomized, placebo-controlled, double-blind phase III trial. Int J Clin Oncol 2015 ; 20 : 198-206.
PubMed
8) Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance : intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 2000 ; 93 : 409-17.
PubMed
P.145 掲載の参考文献
1) World Health Organization. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018.
PubMed
2) 日本緩和医療学会ガイドライン統括委員会編. 薬剤に関する臨床疑問. がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020. p.107-11.
 
3) 鈴木勉. 疼痛克服とDDS. Drug Delivery Syst 2005 ; 20 : 505-12.
 
4) Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology 2016 ; 150 : 1393-407.
 
5) Larkin PJ, Cherny NI, La Carpia D, et al. Diagnosis, assessment and management of constipation in advanced cancer : ESMO Clinical Practice Guidelines. Ann Oncol 2018 ; 29 (Suppl 4) : iv111-25.
 
6) Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain : evidence-based recommendations from the EAPC. Lancet Oncol 2012 ; 13 : e58-68.
PubMed
7) 余宮きのみ. オピオイド誘発性便秘症における治療薬の選び方と使い方 : 経口便秘治療薬. 薬局 2019 ; 70 : 1297-304.
 
8) Arakawa K, Ishigami T, Nakai-Sugiyama M, et al. Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice. PLoS One 2019 ; 14 : e0218096.
PubMed
9) Layer P, Stanghellini V. Review article : linaclotide for the management of irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2014 ; 39 : 371-84.
PubMed
10) Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol 2014 ; 7 : 167-75.
PubMed
11) Schiller LR, Emmett M, Santa Ana CA, et al. Osmotic effects of polyethylene glycol. Gastroenterology 1988 ; 94 : 933-41.
PubMed
12) Hammer HF, Santa Ana CA, Schiller LR, et al. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest 1989 ; 84 : 1056-62.
PubMed
13) Esmadi M, Ahmad D, Hewlett A. Efficacy of naldemedine for the treatment of opioid-induced constipation : a meta-analysis. J Gastrointestin Liver Dis 2019 ; 28 : 41-6.
PubMed
14) McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain : a systematic review. J Pain 2003 ; 4 : 231-56.
 
15) Bush SH, Bruera E. The assessment and management of delirium in cancer patients. Oncologist 2009 ; 14 : 1039-49.
PubMed
16) Tsukuura H, Miyazaki M, Morita T, et al. Efficacy of prophylactic treatment for oxycodone-induced nausea and vomiting among patients with cancer pain (POINT) : a randomized, placebo-controlled, double-blind trial. Oncologist 2018 ; 23 : 367-74.
 
17) Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 2000 ; 41 : 356-9.
PubMed
18) Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer : a prospective study. Arch Intern Med 2000 ; 160 : 786-94.
 
19) Bruera E, Bush SH, Willey J, et al. Impact of delirium and recall on the level or distress in patients with advanced cancer and their family caregivers. Cancer 2009 ; 115 : 2004-12.
PubMed
20) Neufeld KJ, Yue J, Robinson TN, et al. Antipsychotic medication for prevention and treatment of delirium in hospitalized adults : a systematic review and meta-analysis. J Am Geriatr Soc 2016 ; 64 : 705-14.
PubMed
21) Agar MR, Lawlor PG, Quinn S, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care : a randomized clinical trial. JAMA Intern Med 2017 ; 177 : 34-42.
PubMed
22) Woodward OB, Naraen S, Naraen A. Opioid-induced myoclonus and hyperalgesia following a short course of low-dose oral morphine. Br J Pain 2017 ; 11 : 32-5.
 
23) Colvin LA, Bull F, Hales TG. Perioperative opioid analgesia-when is enough too much? A review of opioid-induced tolerance and hyperalgesia. Lancet 2019 ; 393 : 1558-68.
 
24) Tompkins DA, Campbell CM. Opioid-induced hyperalgesia : clinically relevant or extraneous research phenomenon? Curr Pain Headache Rep 2011 ; 15 : 129-36.
PubMed
25) Merdin A, Merdin FA, Gunduz S, et al. Opioid endocrinopathy : a clinical problem in patients with cancer pain. Exp Ther Med 2016 ; 11 : 1819-22.
PubMed
P.155 掲載の参考文献
1) Zech DFJ, Grond S, Lynch J, et al. Validation of World Health Organization Guidelines for cancer pain relief : a 10-year prospective study. Pain 1995 ; 63 : 65-76.
PubMed
2) Clevenger L, Schrept A, Degeest K, et al. Sleep disturbance, distress and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer 2013 ; 119 : 3234-41.
PubMed
3) Bennett MI, Kaasa S, Barke A, et al. The IASP classification of chronic pain for ICD-11 : chronic cancer-related pain. Pain 2019 ; 160 : 38-44.
PubMed
4) World Health Organization. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018.
PubMed
5) 住谷瑞穂, 住谷昌彦. 神経障害性疼痛に対する薬物療法と治療の留意点. 脊髄外科 2019 ; 33 : 246-50.
 
6) Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy : a randomized clinical trial. JAMA 2013 ; 309 : 1359-67.
PubMed
7) Sullivan DR, Forsberg CW, Ganzini L, et al. Longitudinal changes in depression symptoms and survival among patients with lung cancer : a national cohort assessment. J Clin Oncol 2016 ; 34 : 3984-91.
PubMed
8) Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin or their combination for neuropathic pain. N Engl J Med 2005 ; 352 : 1324-34.
PubMed
9) Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain : evidence-based recommendations. Pain 2007 ; 132 : 237-51.
PubMed
10) Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults : a systematic review and meta-analysis. Lancet Neurol 2015 ; 14 : 162-73.
PubMed
11) Sumitani M, Nishizawa D, Hozumi J, et al. Genetic implications in quality palliative care and preventing opioid crisis in cancer-related pain management. J Neurosci Res 2022 ; 100 : 362-72.
PubMed
12) Ando M, Sumitani M, Sakamura M, et al. Tele virtual reality-based peer support programme for cancer patients : a preliminary feasibility and acceptability study. Br J Cancer Res 2020 ; 3 : 443-8.
 
P.162 掲載の参考文献
1) 日本臨床腫瘍学会編. 骨転移診療ガイドライン. 東京 : 南江堂 ; 2015.
 
2) Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer : a randomized, placebo-controlled trial. J Clin Oncol 2005 ; 23 : 3314-21.
 
3) Saad F, Chen YM, Gleason DM, et al. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007 ; 5 : 390-6.
PubMed
4) Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors : a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003 ; 21 : 3150-7.
 
5) Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study. Lancet 2011 ; 377 : 813-22.
PubMed
6) Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer : a randomized, double-blind study. J Clin Oncol 2010 ; 28 : 5132-9.
PubMed
7) Rich SE, Chow R, Raman S, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiother Oncol 2018 ; 126 : 547-57.
 
8) Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain : randomised comparison with a multifraction schedule over 12 months of patient follow-up. Radiother Oncol 1999 ; 52 : 111-21.
PubMed
9) Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases : a systematic review. J Clin Oncol 2007 ; 25 : 1423-36.
 
10) Huisman M, van den Bosch MA, Wijlemans JW, et al. Effectiveness of reirradiation for painful bone metastases : a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2012 ; 84 : 8-14.
PubMed
11) Sahgal A, Myrehaug SD, Siva S, et al. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases : an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol 2021 ; 22 : 1023-33.
PubMed
12) Roque I Figuls M, Martinez-Zapata MJ, Scott-Brown M, et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2011 ; (7) : CD003347.
 
13) Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013 ; 369 : 213-23.
PubMed
14) Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET) : a randomised, phase 2, open-label trial. Lancet 2019 ; 393 : 2051-8.
 
P.168 掲載の参考文献
1) Indo Y. Nerve growth factor and the physiology of pain : lessons from congenital insensitivity to pain with anhidrosis. Clin Genet 2012 ; 82 : 341-50.
PubMed
2) Nielsen CS, Stubhaug A, Price DD, et al. Individual differences in pain sensitivity : genetic and environmental contributions. Pain 2008 ; 136 : 21-9.
PubMed
3) Angst MS, Phillips NG, Drover DR, et al. Pain sensitivity and opioid analgesia : a pharmacogenomic twin study. Pain 2012 ; 153 : 1397-409.
PubMed
4) Angst MS, Lazzeroni LC, Phillips NG, et al. Aversive and reinforcing opioid effects : a pharmacogenomic twin study. Anesthesiology 2012 ; 117 : 22-37.
PubMed
5) 西澤大輔, 福田謙一, 林田眞和ほか. 痛みの遺伝子多型についての基礎研究と臨床研究. 麻酔 2015 ; 64 (増刊) : S177-84.
Medical*Online
6) Owusu Obeng A, Hamadeh I, Smith M. Review of opioid pharmacogenetics and considerations for pain management. Pharmacotherapy 2017 ; 37 : 1105-21.
PubMed
7) Crews KR, Monte AA, Huddart R, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther 2021 ; 110 : 888-96.
PubMed
8) Ren ZY, Xu XQ, Bao YP, et al. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain : a systematic review and meta-analysis. Pain Physician 2015 ; 18 : 131-52.
PubMed
9) Choi SW, Lam DMH, Wong SSC, et al. Effects of single nucleotide polymorphisms on surgical and postsurgical opioid requirements : a systematic review and meta-analysis. Clin J Pain 2017 ; 33 : 1117-30.
PubMed
10) Kuip EJ, Zandvliet ML, Koolen SL, et al. A review of factors explaining variability in fentanyl pharmacokinetics ; focus on implications for cancer patients. Br J Clin Pharmacol 2017 ; 83 : 294-313.
PubMed
11) Hwang IC, Park JY, Myung SK, et al. OPRM1 A118G gene variant and postoperative opioid requirement : a systematic review and meta-analysis. Anesthesiology 2014 ; 121 : 825-34.
PubMed
12) Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav 2014 ; 123 : 25-33.
PubMed
13) Nishizawa D, Nagashima M, Katoh R, et al. Association between KCNJ6 (GIRK2) gene polymorphisms and postoperative analgesic requirements after major abdominal surgery. PLoS One 2009 ; 4 : e7060.
PubMed
14) Bruehl S, Denton JS, Lonergan D, et al. Associations between KCNJ6 (GIRK2) gene polymorphisms and pain-related phenotypes. Pain 2013 ; 154 : 2853-9.
PubMed
15) Nishizawa D, Fukuda K, Kasai S, et al. Association between KCNJ6 (GIRK2) gene polymorphism rs2835859 and post-operative analgesia, pain sensitivity, and nicotine dependence. J Pharmacol Sci 2014 ; 126 : 253-63.
PubMed
16) Kumar D, Deb I, Chakraborty J, et al. A polymorphism of the CREB binding protein (CREBBP) gene is a risk factor for addiction. Brain Res 2011 ; 1406 : 59-64.
PubMed
17) Pal A, Chakraborty J, Das S. Association of CREB1 gene polymorphism with drug seeking behaviour in eastern Indian addicts. Neurosci Lett 2014 ; 570 : 53-7.
PubMed
18) Nishizawa D, Fukuda K, Kasai S, et al. Genome-wide association study identifies a potent locus associated with human opioid sensitivity. Mol Psychiatry 2014 ; 19 : 55-62.
 

IV 鎮痛補助薬

P.183 掲載の参考文献
1) 加藤正樹, 木下利彦. NaSSAの果たすべき役割とその可能性. 臨精薬理 2010 ; 13 : 1891-900.
 
2) Verdu B, Decosterd I, Buclin T, et al. Antidepressants for the treatment of chronic pain. Drugs 2008 ; 68 : 2611-32.
PubMed
3) Grassi L, Nanni MG, Rodin G, et al. The use of antidepressants in oncology : a review and practical tips for oncologists. Ann Oncol 2018 ; 29 : 101-11.
PubMed
4) Brocken P, Prins JB, Dekhuijzen PN, et al. The faster the better? -a systematic review on distress in the diagnostic phase of suspected cancer, and the influence of rapid diagnostic pathways. Psychooncology 2012 ; 21 : 1-10.
 
5) Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain : evidence-based recommendations. Pain 2007 ; 132 : 237-51.
PubMed
6) Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults : a systematic review and meta-analysis. Lancet Neurol 2015 ; 14 : 162-73.
PubMed
7) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン改訂版作成ワーキンググループ編. 神経障害性疼痛薬物療法ガイドライン 改訂第2版. 東京 : 真興交易医書出版部 ; 2016.
 
8) World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018. https://apps.who.int/iris/handle/10665/279700 (accessed June 4, 2021)
 
9) 日本緩和医療学会ガイドライン統括委員会編. がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020.
 
10) Paice JA, Portenoy R, Lacchetti C, et al. Management of chronic pain in survivors of adult cancers : American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2016 ; 34 : 3325-45.
 
11) Hirayama Y, Ishitani K, Sato Y, et al. Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy : a pilot randomized trial. Int J Clin Oncol 2015 ; 20 : 866-71.
PubMed
12) Farshchian N, Alavi A, Heydarheydari S, et al. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 2018 ; 82 : 787-93.
PubMed
13) Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers : ASCO guideline update. J Clin Oncol 2020 ; 38 : 3325-48.
PubMed
14) Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med 2004 ; 164 : 2367-70.
PubMed
15) 日本ペインクリニック学会・日本麻酔科学会・日本区域麻酔学会合同抗血栓療法中の区域麻酔・神経ブロックガイドライン作成ワーキンググループ編. 抗血栓療法中の区域麻酔・神経ブロックガイドライン. 2016. https://anesth.or.jp/files/pdf/guideline_kouketsusen.pdf (accessed June 4, 2021)
 
16) 沢井製薬. アミトリプチリン塩酸塩錠10 mg「サワイ」/アミトソプチリン塩酸塩錠25 mg「サワイ」. 添付文書. 2019年7月改訂 (第19版).
 
17) 塩野義製薬. サインバルタ(R) カプセル20 mg/サインバルタ(R) カプセル30 mg. 添付文書. 2020年2月改訂 (第2版).
 
18) Iosifescu DV, Alpert JE, Fava M. Antidepressants : clinical management. In : Smith HS, editor. Drugs for pain. Philadelphia : Hanley & Belfus ; 2003. p.223-40.
 
19) Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants : a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008 ; 22 : 343-96.
PubMed
20) 精神医学講座担当者会議監修. 上島国利, 樋口輝彦, 野村総一郎編. 気分障害治療ガイドライン. 第2版. 東京 : 医学書院 ; 2010. p.66.
 
21) Jongen JL, Huijsman ML, Jessurun J, et al. The evidence for pharmacologic treatment of neuropathic cancer pain : beneficial and adverse effects. J Pain Symptom Manage 2013 ; 46 : 581-90.e1.
 
22) Saarto T, Wiffen PJ. Antidepressants for neuropathic pain : a Cochrane review. J Neurol Neurosurg Psychiatry 2010 ; 81 : 1372-3.
PubMed
23) 大日本住友製薬. ノリトレン(R) 錠10 mg/ノリトレン(R) 錠25 mg. 添付文書. 2020年3月改訂 (第15版).
 
24) 厚生労働省. 重篤副作用疾患別対応マニュアル悪性症候群. 2008年. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1j01.pdf (accessed June 4, 2021)
 
25) 厚生労働省. 重篤副作用疾患別対応マニュアルセロトニン症候群. 2021年4月改定. https://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1j13-r03.pdf (accessed June 4, 2021)
 
26) 田中尚美, 堀美智子. 薬を極めて服薬指導 (第15回) デュロキセチン塩酸塩. 調剤と情報 2012 ; 18 : 917-23.
 
27) 平田和彦, 比嘉和夫, 廣田一紀ほか. 新たな神経障害痛の治療戦略三環系抗うつ薬の臨床. 日臨麻会誌 2013 ; 33 : 51-5.
 
28) Robinson MJ, Ahl J, Meyers AL, et al. Management of painful symptoms with duloxetine : a review of the efficacy in pre-clinical and clinical studies. Curr Drug Ther 2011 ; 6 : 121-36.
 
29) 平山泰生. 化学療法誘発性末梢神経障害 (CIPN) の症状と対応 Grade 3 以上は被疑薬の減量・中止を慎重に検討, 運動療法は有用. Clinic Magazine 2020 ; 47 : 9-12.
Medical*Online
P.191 掲載の参考文献
1) 「がん社会学」に関する研究グループ. 2013 がん体験者の悩みや負担等に関する実態調査報告書 : がんと向き合った4,054人の声. 2016. https://www.mhlw.go.jp/file/05-Shingikai-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka/0000129860.pdf
 
2) 仙波恵美子. ストレスにより痛みが増強する脳メカニズム. 日緩和医療薬誌 2010 ; 3 : 73-84.
 
3) 浦部晶夫, 島田和幸, 川合眞一ほか編. 抗不安薬, 睡眠薬. 今日の治療薬 2021. 第43版. 東京 : 南江堂 ; 2021. p.892-901.
 
4) 徳丸淑江, 塩入俊樹. 抗不安薬の基礎. 老年精医誌 2019 ; 30 : 795-804.
Medical*Online
5) Howard P, Twycross R, Shuster J, et al. Benzodiazepines. J Pain Symptom Manage 2014 ; 47 : 955-64.
PubMed
6) Vuilleumier PH, Besson M, Desmeules J, et al. Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain : a randomized placebo-controlled study. PLoS One 2013 ; 8 : e43896.
 
7) 日本緩和医療学会ガイドライン統括委員会編. 鎮痛補助薬. がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020. p.87-92.
 
8) 日本医師会監修. 新版がん緩和ケアガイドブック. 東京 : 青海社 ; 2017.
 
9) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン改訂版作成ワーキンググループ編. 抗てんかん薬. 神経障害性疼痛薬物療法ガイドライン 改訂第2版. 東京 : 真興交易医書出版部 ; 2016. p.80-3.
 
10) Leeuw M, Goossens ME, Linton SJ, et al. The fear-avoidance model of musculoskeletal pain : current state of scientific evidence. J Behav Med 2007 ; 30 : 77-94.
PubMed
11) パニック障害の治療法の最適化と治療ガイドラインの策定に関する研究班. パニック障害の治療ガイドライン. 2008. http://hikumano.umin.ac.jp/PD_guideline.pdf
 
12) 森下茂. ベンゾジアゼピン系抗不安薬の適正使用について. 京都医会誌 2021 ; 68 : 87-96.
Medical*Online
P.201 掲載の参考文献
1) Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006 ; 13 : 1153-69.
PubMed
2) 日本緩和医療薬学会企画委員会編. 鎮痛補助薬. 臨床緩和医療薬学. 東京 : 真興交易医書出版部 ; 2008. p.78-92.
 
3) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン改訂版作成ワーキンググループ編. カルシウム (Ca2+) チャネルα2δリガンド. 神経障害性疼痛薬物療法ガイドライン 改訂第2版. 東京 : 真興交易医書出版部 ; 2016. p.57-8.
 
4) 小川節郎編著. 抗けいれん薬. 医療従事者のための痛みガイドブック. 東京 : 技術評論社 ; 2015. p.107-9.
 
5) 金井昭文. 抗てんかん薬. 痛みの構造で考える鎮痛薬の選択. 東京 : 真興交易医書出版部 ; 2019. p.60-9.
 
6) 井関雅子. 抗痙攣薬-神経障害性疼痛の薬物療法ガイドラインと私の選択法-. ペインクリニック 2016 ; 37 : 35-44.
Medical*Online
7) Bauer CS, Nieto-Rostro M, Rahman W, et al. The increased trafficking of the calcium channel subunit α2δ-1 to presynaptic terminals in neuropathic pain is inhibited by the α2δ ligand pregabalin. J Neurosci 2009 ; 29 : 4076-88.
 
8) Taylor CP. Mechanisms of analgesia by gabapentin and pregabalin-calcium channel alpha2-delta [Cavalpha2-delta] ligands. Pain 2009 ; 142 : 13-6.
PubMed
9) Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α2δ-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect 2016 ; 4 : e00205.
 
10) Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Data-base Syst Rev 2017 ; 6 : CD007938.
PubMed
11) Tanabe M, Takasu K, Takeuchi Y, et al. Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury. J Neurosci Res 2008 ; 86 : 3258-64.
PubMed
12) Frampton JE. Pregabalin : a review of its use in adults with generalized anxiety disorder. CNS Drugs 2014 ; 28 : 835-54.
PubMed
13) Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia-an overview of Cochrane reviews. Cochrane Database Syst Rev 2013 ; 2013 : CD010567.
PubMed
14) O'Connor AB, Dworkin RH. Treatment of neuropathic pain : an overview of recent guidelines. Am J Med 2009 ; 122 (10 Suppl) : S22-32.
 
15) Clarke H, Bonin RP, Orser BA, et al. The prevention of chronic postsurgical pain using gabapentin and pregabalin : a combined systematic review and meta-analysis. Anesth Analg 2012 ; 115 : 428-42.
PubMed
16) Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019 ; 1 : CD007076.
PubMed
17) Derry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev 2016 ; 9 : CD011790.
PubMed
18) Kato J, Matsui N, Kakehi Y, et al. Mirogabalin for the management of postherpetic neuralgia : a randomized, double-blind, placebo-controlled phase 3 study in Asian patients. Pain 2019 ; 160 : 1175-85.
PubMed
19) Baba M, Matsui N, Kuroha M, et al. Mirogabalin for the treatment of diabetic peripheral neuropathic pain : a randomized, double-blind, placebo-controlled phase III study in Asian patients. J Diabetes Investig 2019 ; 10 : 1299-306.
PubMed
20) Hoppe C, Rademacher M, Hoffmann JM, et al. Bodyweight gain under pregabalin therapy in epilepsy : mitigation by counseling patients? Seizure 2008 ; 17 : 327-32.
PubMed
21) Stephen LJ, Parker P, Kelly K, et al. Adjunctive pregabalin for uncontrolled partial-onset seizures : findings from a prospective audit. Acta Neurol Scand 2011 ; 124 : 142-5.
PubMed
22) Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs 2017 ; 77 : 403-26.
PubMed
23) Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014 ; 2014 : CD005451.
PubMed
24) Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2005 ; 3 : CD001133.
PubMed
25) McCleane GJ. Intravenous infusion of phenytoin relieves neuropathic pain : a randomized, double-blinded, placebo-controlled, crossover study. Anesth Analg 1999 ; 89 : 985-8.
PubMed
26) Chang VT. Intravenous phenytoin in the management of crescendo pelvic cancer-related pain. J Pain Symptom Manage 1997 ; 13 : 238-40.
 
27) Besson M, Matthey A, Daali Y, et al. GABAergic modulation in central sensitization in humans : a randomized placebo-controlled pharamacokinetic-pharmacodynamic study comparing clobazam with clonazepam in healthy volunteers. Pain 2015 ; 156 : 397-404.
 
28) Liu YF, Kim Y, Yoo T, et al. Burning mouth syndrome : a systematic review of treatments. Oral Dis 2018 ; 24 : 325-34.
PubMed
29) Vuilleumier PH, Besson M, Desmeules J, et al. Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in human experimental pain : a randomized placebo-controlled study. PLoS One 2013 ; 8 : e43896.
 
30) Hugel H, Ellershaw JE, Dickman A. Clonazepam as an adjuvant analgesic in patients with cancer-related neuropathic pain. J Pain Symptom Manage 2003 ; 26 : 1073-4.
PubMed
31) de las Cuevas C, Sanz E, de la Fuente J. Benzodiazepines : more "behavioural" addiction than dependence. Psychopharmacology (Berl) 2003 ; 167 : 297-303.
PubMed
32) Johannessen CU. Mechanisms of action of valproate : a commentatory. Neurochem Int 2000 ; 37 : 103-10.
PubMed
33) Chan K, MaassenVanDenBrink A. Glutamate receptor antagonists in the management of migraine. Drugs 2014 ; 74 : 1165-76.
PubMed
34) Linde M, Mulleners WM, Chronicle EP, et al. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013 ; 24 : CD010611.
 
35) Hardy JR, Rees EA, Gwilliam B, et al. A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J Pain Symptom Manage 2001 ; 21 : 204-9.
PubMed
36) Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005 ; 64 : 1874-8.
PubMed
37) White HS, Brown SD, Woodhead JH, et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997 ; 28 : 167-79.
PubMed
38) Silberstein SD. Topiramate in migraine prevention : a 2016 perspective. Headache 2017 ; 57 : 165-78.
PubMed
39) Diener HC, Bussone G, Van Oene JC, et al. Topiramate reduces headache days in chronic migraine : a randomized, double-blind, placebo-controlled study. Cephalalgia 2007 ; 27 : 814-23.
 
P.208 掲載の参考文献
1) 渡邉修造. 神経因性疼痛治療薬としての電位依存性ナトリウムチャネル遮断薬の探索研究. 日薬理誌 2012 ; 140 : 201-5.
Medical*Online
2) Devor M. Sodium channels and mechanism of neuropathic pain. J Pain 2006 ; 7 (1 Suppl 1) : S3-12.
 
3) Kamei J, Hitosugi H, Kasuya Y. Effects of mexiletine on formalin-induced nociceptive responses in mice. Res Commun Chem Pathol Pharmacol 1993 ; 80 : 153-62.
PubMed
4) Kamei J, Saitoh A, Kasuya Y. Involvement of delta 1-opioid receptors in the antinociceptive effects of mexiletine in mice. Neurosci Lett 1995 ; 196 : 169-72.
PubMed
5) Suzuki M, Narita M, Hasegawa M, et al. Sensation of abdominal pain induced by peritoneal carcinomatosis is accompanied by changes in the expression of substance P and μ-opioid receptors in the spinal cord of mice. Anesthesiology 2012 ; 117 : 847-56.
 
6) Tagami K, Miura T, Suzuki M, et al. Analgesic effectiveness of systemic lidocaine administration for abdominal cancer pain caused by peritoneal carcinomatosis : a case series of 10 patients. J Palliat Med 2016 ; 19 : 1247-8.
 
7) World Health Organization. Cancer pain relief : with a guide to opioid availability. 2nd ed. 1996.
 
8) World Health Organization. WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018.
PubMed
9) Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain : ESMO Clinical Practice Guidelines. Ann Oncol 2012 ; 23 Suppl 7 : vii139-54.
 
10) Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients : ESMO Clinical Practice Guidelines. Ann Oncol 2018 ; 29 Suppl 4 : iv166-91.
 
11) Challapalli V, Tremont-Lukats IW, McNicol ED, et al. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database Syst Rev 2019 ; 2019. doi : 10.1002/14651858.CD003345.pub2.
 
12) Swarm RA, Paice JA, Anghelescu DL, et al. Adult cancer pain, Version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019 ; 17 : 977-1007.
PubMed
13) Lee JT, Sanderson CR, Xuan W, et al. Lidocaine for cancer pain in adults : a systematic review and meta-analysis. J Palliat Med 2019 ; 22 : 326-34.
PubMed
14) Bruera E, Ripamonti C, Brenneis C, et al. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage 1992 ; 7 : 138-40.
PubMed
15) Torres OC, Allier MMG, Olvera MJ. Comparison between dexmedetomidine infusion vs. lidocaine intravenous infusion for treatment of severe pain in palliative care patients under opioid treatment. Rev Soc Esp Dolor 2015 ; 22 : 7-12.
 
16) Ellemann K, Sjogren P, Banning AM, et al. Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clin J Pain 1989 ; 5 : 291-4.
PubMed
17) Sharma S, Rajagopal MR, Palat G, et al. A phase II pilot study to evaluate use of intravenous lidocaine for opioid-refractory pain in cancer patients. J Pain Symptom Manage 2009 ; 37 : 85-93.
PubMed
18) 太陽ファルマ. メキシチール(R) カプセル50 mg/メキシチール(R) カプセル100 mg/MEXITIL(R). 医薬品インタビューフォーム. 2019年10月 (改訂第11版).
 
19) Atayee RS, Naidu D, Geiger-Hayes J, et al. A multi-centered case series highlighting the clinical use and dosing of lidocaine and mexiletine for refractory cancer pain. J Pain Palliat Care Pharmacother 2020 ; 34 : 90-8.
PubMed
20) エーザイ. タンボコール(R) 錠50 mg/タンボコール(R) 錠100 mg/タンボコール(R) 細粒10%. 医薬品インタビューフォーム. 2015年6月改訂 (改訂第12版).
 
21) 植木隆介, 森山萬秀, 野間秀樹ほか. 神経因性疼痛に対するフレカイニドの鎮痛作用に関する検討-メキシレチン内服効果が不十分な症例に対するフレカイニドの鎮痛効果-. 日臨麻会誌 2006 ; 26 : 266-71.
 
22) 日本麻酔科学会. XI. ペイン 7. 抗不整脈薬. 医薬品ガイドライン. 第3版 4訂. 2019. p.551-8.
 
23) 日本麻酔科学会. 局所麻酔薬中毒への対応プラクティカルガイド. https://anesth.or.jp/files/pdf/practical_localanesthesia.pdf (accessed July 14, 2021)
 
24) Ferrante FM, Paggioli J, Cherukuri S, et al. The analgesic response to intravenous lidocaine in the treatment of neuropathic pain. Anesth Analg 1996 ; 82 : 91-7.
PubMed
25) 中川左理. 局所麻酔薬の全身投与. Twycross R, Wilcock A, Howard P編. 武田文和, 鈴木勉監訳. トワイクロス先生の緩和ケア処方薬. 第2版. 東京 : 医学書院 ; 2017. p.76-82.
 
P.220 掲載の参考文献
1) 杉山陽子. 痛みの機序から考える鎮痛補助薬. 日臨麻会誌 2017 ; 37 : 361-7.
Medical*Online
2) Gu X, Zhang J, Ma Z, et al. The role of N-methyl-D-aspartate receptor subunit NR2B in spinal cord in cancer pain. Eur J Pain 2010 ; 14 ; 496-502.
 
3) Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991 ; 251 : 85-7.
PubMed
4) Shimoyama N, Shimoyama M, Inturrisi CE, et al. Ketamine attenuates and reverses morphine tolerance in rodents. Anesthesiology 1996 ; 85 : 1357-66.
PubMed
5) Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology 1997 ; 86 : 903-17.
 
6) 塩川浩輝. 4 痛みを修飾する脊髄後角介在神経のNMDA受容体の役割. LiSA 2018 ; 25 別冊秋 : 31-7.
 
7) 渋谷健, 堀部真広, 佐々木康雄ほか. 2- (O-Chlorophenyl) -2-Methylamino-Cyclohexanone HCl (CI-581) の薬理学的検索, 殊に中枢神経系に対する作用. 東医大誌 1969 ; 27 : 249-56.
Medical*Online
8) 第一三共. ケタラール. 医薬品インタビューフォーム. 2012年6月改訂 (第9版).
 
9) Corssen G, Miyasaka M, Domino EF. Changing concepts in pain control during surgery : dissociative anesthesia with CI-581. A progress report. Anesth Analg 1968 ; 47 : 746-59.
PubMed
10) Green SM, Roback MG, Kennedy RM, et al. Clinical practice guideline for emergency department ketamine dissociative sedation : 2011 update. Ann Emerg Med 2011 ; 57 : 449-61.
PubMed
11) Bell JD. In vogue : Ketamine for neuroprotection in acute neurologic injury. Anesth Analg 2017 ; 124 : 1237-43.
PubMed
12) Hirota K, Lambert DG. Ketamine : its mechanism (s) of action and unusual clinical uses. Br J Anaesth 1996 ; 77 : 441-4.
PubMed
13) Shimoyama M, Shimoyama N, Gorman AL, et al. Oral ketamine is antinociceptive in the rat formalin test : role of the metabolite, norketamine. Pain 1999 ; 81 : 85-93.
PubMed
14) Seeman P, Ko F, Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 2005 ; 10 : 877-83.
 
15) Nishimura M, Sato K, Okada T, et al. Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology 1998 ; 88 : 768-74.
PubMed
16) Schwenk ES, Viscusi ER, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med 2018 ; 43 : 456-66.
 
17) 水野樹, 杉本清治, 鎌倉知子ほか. 局所性表在痛に対するケタミン硬膜外注入の有用性. 麻酔 2001 ; 50 : 658-61.
Medical*Online
18) 水野樹, 杉本清治, 大森貴夫ほか. ケタミン持続点滴療法が奏効した断端痛の1症例. 麻酔 2001 ; 50 : 770-2.
Medical*Online
19) 丸山洋一, 猿木信裕. がん専門診療施設の医師による鎮痛補助薬の評価. ペインクリニック 2006 ; 27 : 1563-70.
 
20) Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of postoperative pain : a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain 2016 ; 17 : 131-57.
 
21) Chapman EJ, Edwards Z, Boland JW, et al. Practice review : evidence-based and effective management of pain in patients with advanced cancer. Palliat Med 2020 ; 34 : 445-53.
 
22) Ahmedzai S. New approaches to pain control in patients with cancer. Eur J Cancer 1997 ; 33 Suppl 6 : S8-14.
 
23) Kotlinska-Lemieszek A, Juczak J. Subanesthetic ketamine : an essential adjuvant for intractable cancer pain. J Pain Symptom Manage 2004 ; 28 : 100-2.
PubMed
24) Amin P, Roeland E, Atayee R. Case report : efficacy and tolerability of ketamine in opioid-refractory cancer pain. J Pain Palliat Care Pharmacother 2014 ; 28 : 233-42.
PubMed
25) Bell RF. Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain 1999 ; 83 : 101-3.
PubMed
26) Culp C, Kim HK, Abdi S. Ketamine use for cancer and chronic pain management. Front Pharmacol 2021 ; 11 : 599721.
PubMed
27) Dickenson AH. Neurophysiology of opioid poorly responsive pain. Cancer Surv 1994 ; 21 : 5-16.
PubMed
28) Fine PG. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain. J Pain Symptom Manage 1999 ; 17 : 296-300.
PubMed
29) Finkel JC, Pestieau SR, Quezado ZM. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain 2007 ; 8 : 515-21.
PubMed
30) Grande LA, O'Donnell BR, Fitzgibbon DR, et al. Ultra-low dose ketamine and memantine treatment for pain in an opioid-tolerant oncology patient. Anesth Analg 2008 ; 107 : 1380-3.
 
31) Kreutzwiser D, Tawfic QA. Expanding role of NMDA receptor antagonists in the management of pain. CNS Drugs 2019 ; 33 : 347-74.
PubMed
32) Lossignol DA, Obiols-Portis M, Body JJ. Successful use of ketamine for intractable cancer pain. Support Care Cancer 2005 ; 13 : 188-93.
PubMed
33) McDonnell FJ, Sloan JW, Hamann SR. Advances in cancer pain management. Curr Oncol Rep 2000 ; 2 : 351-7.
PubMed
34) Mercadante S. Ketamine in cancer pain : an update. Palliat Med 1996 ; 10 : 225-30.
PubMed
35) Okon T. Ketamine : an introduction for the pain and palliative medicine physician. Pain Physician 2007 ; 10 ; 493-500.
PubMed
36) Patel S, Tatachar V, Singh AB, et al. Low-dose ketamine as an adjuvant for pain control in a cancer patient : a case report. Ann Palliat Med 2021 ; 10 : 8328-33.
 
37) Sosnowski M. Pain management : physiopathology, future research and endpoints. Support Care Cancer 1993 ; 1 : 79-88.
PubMed
38) Waldfogel JM, Nesbit S, Cohen SP, et al. Successful treatment of opioid-refractory cancer pain with short-course, low-dose ketamine. J Pain Palliat Care Pharmacother 2016 ; 30 : 294-7.
PubMed
39) Campbell-Fleming JM, Williams A. The use of ketamine as adjuvant therapy to control severe pain. Clin J Oncol Nurs 2008 ; 12 : 102-7.
PubMed
40) Mercadante S, Arcuri E, Tirelli W, et al. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy : a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000 ; 20 : 246-52.
PubMed
41) Jackson K, Ashby M, Martin P, et al". Burst"ketamine for refractory cancer pain : an open-label audit of 39 patients. J Pain Symptom Manage 2001 ; 22 : 834-42.
PubMed
42) Jackson K, Ashby M, Howell D, et al. The effectiveness and adverse effects profile of "burst" ketamine in refractory cancer pain : The VCOG PM 1-00 study. J Palliat Care 2010 ; 26 : 176-83.
PubMed
43) Kannan TR, Saxena A, Bhatnagar S, et al. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 2002 ; 23 : 60-5.
PubMed
44) Ogawa S, Kanamaru T, Noda K, et al. Intravenous microdrip infusion of ketamine in subanesthetic doses for intractable terminal cancer pain. Pain Clin 1994 ; 7 : 125-9.
 
45) 佐藤哲, 片岡智美, 篠道弘ほか. 神経障害性疼痛に対する内服薬としてのケタミンの有用性についての検討. Palliat Care Res 2008 ; 3 : 216-20.
 
46) Saito O, Aoe T, Kozikowski A, et al. Ketamine and N-acetylaspartylglutamate peptidase inhibitor exert analgesia in bone cancer pain. Can J Anaesth 2006 ; 53 : 891-8.
 
47) Stefanczyk-Sapieha L, Oneschuk D, Demas M. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. J Palliat Med 2008 ; 11 : 1268-71.
 
48) Tawfic QA. A review of the use of ketamine in pain management. J Opioid Manag 2013 ; 9 : 379-88.
PubMed
49) Mercadante S, Villari P, Ferrera P. Burst ketamine to reverse opioid tolerance in cancer pain. J Pain Symptom Manage 2003 ; 25 : 302-5.
PubMed
50) 竹井清純. オピオイド抵抗性の疼痛に対しバースト・ケタミン療法を施行した1例. Palliat Care Res 2011 ; 6 : 358-64.
 
51) Berger JM, Ryan A, Vadivelu N, et al. Ketamine-fentanyl-midazolam infusion for the control of symptoms in terminal life care. Am J Hosp Palliat Care 2000 ; 17 : 127-34.
PubMed
52) Enck RE. A ketamine, fentanyl, and midazolam infusion for uncontrolled terminal pain and agitation. Am J Hosp Palliat Care 2000 ; 17 : 76-7.
PubMed
53) Oshima E, Tei K, Kayazawa H, et al. Continuous subcutaneous injection of ketamine for cancer pain. Can J Anaesth 1990 ; 37 : 385-6.
PubMed
54) Bell RF. Low-dose subcutaneous ketamine infusion and morphine tolerance. Pain 1999 ; 83 : 101-3.
PubMed
55) Mercadante S, Lodi F, Sapio M, et al. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage 1995 ; 10 : 564-8.
PubMed
56) Benitez-Rosario MA, Feria M, Salinas-Martin A, et al. A retrospective comparison of the dose ratio between subcutaneous and oral ketamine. J Pain Symptom Manage 2003 ; 25 : 400-2.
PubMed
57) Dulin JD, Hardcopf J, Coyne PJ. Iatrogenic oral ketamine overdose in palliative care. J Palliat Med 2021 ; 24 : 148-51.
PubMed
58) Fitzgibbon EJ, Hall P, Schroder C, et al. Low dose ketamine as an analgesic adjuvant in difficult pain syndromes : a strategy for conversion from parenteral to oral ketamine. J Pain Symptom Manage 2002 ; 23 : 165-70.
PubMed
59) Lauretti GR, Lima IC, Reis MP, et al. Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology 1999 ; 90 : 1528-33.
PubMed
60) Singh V, Gillespie TW, Harvey RD. Intranasal ketamine and its potential role in cancer-related pain. Pharmacotherapy 2018 ; 38 : 390-401.
PubMed
61) Fernandes M, Schelotto M, Doldi PM, et al. IMPORTANCE trial : a provisional study-design of a single-center, phase II, double-blinded, placebo-controlled, randomized, 4-week study to compare the efficacy and safety of intranasal esketamine in chronic opioid refractory pain. F1000Res 2021 ; 10 : 42.
 
62) Sen S, Aydin ON, Aydin K. Beneficial effect of low-dose ketamine addition to epidural administration of morphine-bupivacaine mixture for cancer pain in two case. Pain Med 2006 ; 7 : 166-9.
PubMed
63) Yang CY, Wong CS, Chang JY, et al. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth 1996 ; 43 : 379-83.
PubMed
64) Conway M, White N, Jean CS, et al. Use of continuous intravenous ketamine for end-stage cancer pain in children. J Pediatr Oncol Nurs 2009 ; 26 : 100-6.
 
65) Anghelescu DL, Oakes LL. Ketamine use for reduction of opioid tolerance in a 5-year-old girl with end-stage abdominal neuroblastoma. J Pain Symptom Manage 2005 ; 30 : 1-3.
 
66) Tagami K, Matsuoka H, Ariyoshi K, et al. The current clinical use of adjuvant analgesics for refractory cancer pain in Japan : a nationwide cross-sectional survey. Jpn J Clin Oncol 2020 ; 50 : 1434-41.
PubMed
67) Fallon MT, Wilcock A, Kelly CA, et al. Oral ketamine vs placebo in patients with cancer-related neuropathic pain : a randomized clinical trial. JAMA Oncol 2018 ; 4 : 870-2.
PubMed
68) Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2012 ; 11 : CD003351.
PubMed
69) Bell RF, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst Rev 2017 ; 6 : CD003351.
PubMed
70) Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol 2012 ; 30 : 3611-7.
PubMed
71) Jonkman K, van de Donk T, Dahan A. Ketamine for cancer pain : what is the evidence? Curr Opin Support Palliat Care 2017 ; 11 : 88-92.
PubMed
72) McCaffrey N, Flint T, Kaambwa B, et al. Economic evaluation of the randomised, double-blind, placebo-controlled study of subcutaneous ketamine in the management of chronic cancer pain. Palliat Med 2019 ; 33 : 74-81.
PubMed
73) Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients : ESMO Clinical Practice Guidelines. Ann Oncol 2018 ; 29 Suppl 4 : iv166-91.
 
74) 特定非営利活動法人日本緩和医療学会ガイドライン統括委員会編. CQ15 がん疼痛のある患者に対して, オピオイドに加えて, ケタミンの投与は推奨されるか? がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020. p.138-9.
 
75) Hospira. KETAMINE HYDROCHLORIDE-ketamine hydrochloride injection, solution, concentrate. http://labeling.pfizer.com/ShowLabeling.aspx?id=4485
 
76) Patel P, Sun L. Update on neonatal anesthetic neurotoxicity : insight into molecular mechanisms and relevance to humans. Anesthesiology 2009 ; 110 : 703-8.
PubMed
P.231 掲載の参考文献
1) 光畑裕正. 局所麻酔薬のアナフィラキシー. 日ペインクリニック会誌 2014 ; 21 : 2-9.
Medical*Online
2) Taylor A, McLeod G. Basic pharmacology of local anaesthetics. BJA Educ 2020 ; 20 : 34-41.
 
3) Berde CB, Strichartz GR. Local anesthetics. In : Miller RD, editor. Miller's anesthesia. 8th ed. Philadelphia : Elsevier ; 2015. p.1028-54.
 
4) Christo PJ, Mazloomdoost D. Interventional pain treatments for cancer pain. Ann N Y Acad Sci 2008 ; 1138 : 299-328.
PubMed
5) Sjoberg M, Nitescu P, Appelgren L, et al. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine : bupivacaine dose regimen of 0.5 : 4.75 mg/ml. Anesthesiology 1994 ; 80 : 284-97.
 
6) 服部政治, 吉澤一巳, 益田律子ほか. がん性疼痛に対するくも膜下鎮痛法. 日緩和医療薬誌 2010 ; 3 : 31-6.
 
7) Kedlaya D, Reynolds L, Waldman S. Epidural and intrathecal analgesia for cancer pain. Best Pract Res Clin Anaesthesiol 2002 ; 16 : 651-65.
PubMed
8) Vandermeulen EP, Van Aken H, Vermylen J. Anticoagulants and spinal-epidural anesthesia. Anesth Analg 1994 ; 79 : 1165-77.
PubMed
9) Klepstad P, Kurita GP, Mercadante S, et al. Evidence of peripheral nerve blocks for cancer-related pain : a systematic review. Minerva Anestesiol 2015 ; 81 : 789-93.
PubMed
10) 榎本達也, 高田朋彦, 月山 淑ほか. がん性疼痛に対する神経ブロックの役割. 日緩和医療薬誌 2010 ; 3 : 67-72.
 
11) Bruea E, Ripamonti C, Brenneis C, et al. A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain. J Pain Symptom Manage 1992 ; 7 : 138-40.
 
12) Ellemann K, Sjogren P, Banning AM, et al. Trial of intravenous lidocaine on painful neuropathy in cancer patients. Clin J Pain 1989 ; 5 : 291-4.
PubMed
13) Ripamonti CI, Santini D, Maranzano E, et al. Management of cancer pain : ESMO Clinical Practice Guidelines. Ann Oncol 2012 ; 23 Suppl 7 : vii139-54.
 
14) Lee JT, Sanderson CR, Xuan W, et al. Lidocaine for cancer pain in adults : a systemic review and meta-analysis. J Palliat Med 2019 ; 22 : 326-34.
PubMed
15) Graeme A, McLeod, John F, et al. Local anesthetic systemic toxicity. In : Cousins MJ, Carr DB, Horlocker TT, et al, editors. Cousins and Bridenbaugh's neural blockade in clinical anesthesia and pain medicine. 4th ed. Philadelphia : Lippincott Williams & Wilkins ; 2009. p.114-32.
 
16) 日本麻酔科学会. 局所麻酔薬中毒への対応プラクティカルガイド. 2017.
 

V がん性疼痛に対する各種療法

P.247 掲載の参考文献
1) 高橋弦, 森永達夫, 中村伸一郎ほか. 脊椎およびその周辺組織に由来する痛みの症候学. 脊椎脊髄ジャーナル 1997 ; 10 : 221-5.
 
2) Ohtori S, Takahashi Y, Takahashi K, et al. Sensory innervation of the dorsal portion of the lumbar intervertebral disc in rats. Spine (Phila Pa 1976) 1999 ; 24 : 2295-9.
PubMed
3) 平川奈緒美, 上村裕平, 笹栗智子ほか. 腹腔神経叢ブロック. ペインクリニック 2011 ; 32 : 59-66.
Medical*Online
4) 安部洋一郎. 痛みの治療に必要な局所解剖 2. 胸部交感神経節. ペインクリニック 2020 ; 41 別冊秋 : S365-75.
 
5) 塩谷正弘. 腹腔神経叢ブロック. 若杉文吉監修. 大瀬戸清茂, 塩谷正弘, 長沼芳和ほか編. ペインクリニック-神経ブロック法. 第2版. 東京 : 医学書院 ; 2000. p.170-84.
 
6) 安部洋一郎, 佐伯美奈子, 加藤敦子ほか. 側方アプローチによる不対神経高周波熱凝固法. ペインクリニック 2004 ; 25 : 649-52.
 
7) 日本緩和医療学会緩和医療ガイドライン作成委員会編. 神経ブロック. がん疼痛の薬物療法に関するガイドライン 2010年版. 東京 : 金原出版 ; 2010. p.88-92.
 
8) Mauck WD, Rho RH. The role of neurolytic sympathetic blocks in treating cancer pain. Tech Reg Anesth Pain Manag 2010 ; 14 : 32-9.
 
9) 「慢性疼痛診療システムの均てん化と痛みセンター診療データベースの活用による医療向上を目指す研究」研究班監修. 慢性疼痛診療ガイドライン作成ワーキンググループ編. D. インターベンショナル治療 (神経ブロック) CQ D-4 : 星状神経節ブロックは慢性疼痛に有用か? 慢性疼痛診療ガイドライン. 東京 : 真興交易医書出版部 ; 2021. p.82-3.
 
10) Ohseto K. Contrast radiography and effects of thoracic sympathetic ganglion block-anatomical analysis. J Anesth 1991 ; 5 : 132-41.
PubMed
11) Ohseto K. Efficacy of thoracic sympathetic ganglion block and prediction of complications : clinical evaluation of the anterior paratracheal and posterior paravertebral approaches in 234 patients. J Anesth 1992 ; 6 : 316-31.
PubMed
12) 小川節郎. III. 交感神経ブロック 5. 腹腔神経叢ブロック・内臓神経ブロック (1) 透視下アプローチ. ペインクリニック 2011 ; 32 (別冊春) : S143-51.
Medical*Online
P.257 掲載の参考文献
1) Swarm RA, Karanikolas M, Cousins MJ. Injections, neural blockade, and implant therapies for pain control. In : Hanks G, Cherny NI, Christakis NA, et al, editors. Oxford textbook of palliative medicine. 4th ed. Oxford : Oxford University Press ; 2010. p.734-54.
 
2) 大瀬戸清茂, 仁科博志, 塩谷正弘ほか. 神経根高周波熱凝固で除痛した癌性疼痛の検討. 麻酔 1993 ; 42 : 1177-83.
Medical*Online
3) Nagaro T, Amawaka K, Yamauchi Y, et al. Percutaneous cervical cordotomy and subarachnoid phenol block using fluoroscopy in pain control of costopleural syndrome. Pain 1994 ; 58 : 325-30.
 
4) 若杉文吉. 三叉神経痛の基本的治療 : 臨床像, 神経ブロック療法 (アルコールブロック) の適応と効果. 耳鼻・頭頸外科 1989 ; 61 : 862-8.
 
5) 大瀬戸清茂. 肩甲上神経ブロック. 若杉文吉監修. 大瀬戸清茂, 塩谷正弘, 長沼芳和ほか編. ペインクリニック-神経ブロック法. 第2版. 東京 : 医学書院 ; 2000. p.89-91.
 
6) Wong FC, Lee TW, Yuen KK, et al. Intercostal nerve blockade for cancer pain : effectiveness and selection of patients. Hong Kong Med J 2007 ; 13 : 266-70.
PubMed
7) Falco FJ, Manchikanti L, Datta S, et al. An update of the effectiveness of therapeutic lumber facet joint interventions. Pain Physician 2012 ; 15 : E909-53.
 
8) 宮崎東洋, 村川和重, 佐藤 智ほか. がん患者の筋・筋膜性疼痛に対するトリガーポイント療法の有用性. ペインクリニック 2010 ; 31 : 195-203.
 
P.273 掲載の参考文献
1) Yaksh TL. Analgesic actions of intrathecal opiates in cat and primate. Brain Res 1978 ; 153 : 205-10.
 
2) Yaksh TL, Reddy SV. Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen. Anesthesiology 1981 ; 54 : 451-67.
PubMed
3) Slattery PJ, Boas RA. Newer methods of delivery of opiates for relief of pain. Drugs 1985 ; 30 : 539-51.
PubMed
4) Tung A, Maliniak K, Tenicela R, et al. Intrathecal morphine for intraoperative and postoperative analgesia. JAMA 1980 ; 244 : 2637-8.
PubMed
5) Payne R. Role of epidural and intrathecal narcotics and peptides in the management of cancer pain. Med Clin North Am 1987 ; 71 : 313-27.
PubMed
6) Ferrer-Brechner T. Anesthetic techniques for the management of cancer pain. Cancer 1989 ; 63 (11 Suppl) : 2343-7.
 
7) Lordon SP. Interventional approach to cancer pain. Curr Pain Headache Rep 2002 ; 6 : 202-6.
PubMed
8) Bejjani GK, Karim NO, Tzortzidis F. Intrathecal granuloma after implantation of a morphine pump : case report and review of the literature. Surg Neurol 1997 ; 48 : 288-91.
PubMed
9) Smith TJ, Coyne PJ. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. J Palliat Med 2005 ; 8 : 736-42.
PubMed
10) Dermot RF. Pain in malignant disease. Cancer pain : Management. In : Loeser JD, Butler SH, Chapman CR, et al, editors. Bonica's management of pain. 3rd ed. Philadelphia : Lippincott Williams & Wilkins ; 2001. p.659-703.
 
11) Lema MJ. Invasive analgesia techniques for advanced cancer pain. Surg Oncol Clin N Am 2001 ; 10 : 127-36.
PubMed
12) Turnbull DK, Shepherd DB. Post-dural puncture headache : pathogenesis, prevention and treatment. Br J Anaesth 2003 ; 91 : 718-29.
PubMed
P.278 掲載の参考文献
1) Herndon C. Continuous subcutaneous infusion for pain management. AJPM 2000 ; 10 : 53-9.
 
2) Ellershaw J, Ward C. Care of the dying patient : the last hours or days of life. BMJ 2003 ; 326 : 30-4.
PubMed
3) Masman AD, van Dijk M, Tibboel D, et al. Medication use during end-of-life care in a palliative care centre. Int J Clin Pharm 2015 ; 37 : 767-75.
 
4) Moulin DE, Kreeft JH, Murray-Parsons N, et al. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991 ; 337 : 465-8.
PubMed
5) Herndon CM, Fike DS. Continuous subcutaneous infusion practices of United States hospices. J Pain Symptom Manage 2001 ; 22 : 1027-34.
PubMed
6) 関本剛. 皮下投与法-皮下輸液と持続皮下注射. Cancer Board Square 2019 ; 5 : 140-4.
 
7) 日本緩和医療学会ガイドライン統括委員会編. 海外のがん疼痛ガイドラインの概要. がん疼痛の薬物療法に関するガイドライン 2020年版. 東京 : 金原出版 ; 2020. p.43-52.
 
8) 寳田潤子. 持続皮下注入法. 小川節郎編著. ペインクリニシャンのための新キーワード 135. 東京 : 真興交易医書出版部 ; 2014. p.265-6.
 
9) 第一三共プロファーマ. ナルベイン(R) 注2mg/ナルベイン(R) 注20mg. 添付文書. 2021年9月改訂 (第2版).
 
10) 荒木貢士, 原口 勝. 持続皮下注射刺入部の発赤・硬結の出現頻度とその予防に関する検討. Palliat Care Res 2012 ; 7 : 112-20.
 
11) 粕田晴之. 持続皮下注入. 山口重樹, 下山直人編. 症例で身につくがん疼痛治療薬. 東京 : 羊土社 ; 2014. p.441-5.
 
12) 日本緩和医療学会緩和医療ガイドライン委員会編. 皮下輸液法. 終末期がん患者の輸液療法に関するガイドライン 2013年版. 東京 : 金原出版 ; 2013. p.41-3.
 
P.285 掲載の参考文献
1) 日本緩和医療学会ガイドライン統括委員会編. がん疼痛の薬物療法に関するガイドライン 2020年版. http://www.jspm.ne.jp/guidelines/pain/2020/index.php (accessed July 27, 2021)
 
2) Nelson KA, Glare PA, Walsh D, et al. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage 1997 ; 13 : 262-7.
 
3) Elsner F, Radbruch L, Loick G, et al. Intravenous versus subcutaneous morphine titration in patients with persisting exacerbation of cancer pain. J Palliat Med 2005 ; 8 : 743-50.
PubMed
4) 三原良介, 荘園雅子, 日下仁美ほか. 腹腔鏡下手術後痛に対するフルルビプロフェン, トラマドール塩酸塩の持続静脈内投与の効果の検討. 麻酔 2011 ; 60 : 1364-9.
Medical*Online
5) 名徳倫明, 岡 隆志, 北出尚子ほか. 携帯型持続注入ポンプを想定した緩和医療で使用するフルルビプロフェンアキセチル注と他剤との配合変化に関する評価. 日緩和医療薬誌 2014 ; 7 : 97-103.
 
6) Pang WW, Mok MS, Lin CH, et al. Comparison of patient-controlled analgesia (PCA) with tramadol or morphine. Can J Anaesth 1999 ; 46 : 1030-5.
 
7) 荒木貢士, 原口勝. 持続皮下注射刺入部の発赤・硬結の出現頻度とその予防に関する検討. Palliat Care Res 2012 ; 7 : 112-20.
 
8) Jackson K, Ashby M, Howell D, et al. The effectiveness and adverse effects profile of "burst" ketamine in refractory cancer pain : The VCOG PM 1-00 study. J Palliat Care 2010 ; 26 : 176-83.
PubMed
9) Ferrini R. Parenteral lidocaine for severe intractable pain in six hospice patients continued at home. J Palliat Med 2000 ; 3 : 193-200.
 
10) 厚生労働省. 医療用麻薬適正使用ガイダンス～がん疼痛及び慢性疼痛治療における医療用麻薬の使用と管理のガイダンス～. https://www.mhlw.go.jp/bunya/iyakuhin/yakubuturanyou/other/iryo_tekisei_guide.html (accessed Aug 23, 2021)
 
11) Ryan M, Moynihan TJ, Loprinzi CL, et al. As-needed morphine : yes, but at what dose and at what interval? J Clin Oncol 2005 ; 23 : 3849-52.
PubMed
12) 日本緩和医療学会緩和医療ガイドライン委員会編. がん疼痛の薬物療法に関するガイドライン 2014年版. https://www.jspm.ne.jp/guidelines/pain/2014/index.php (accessed July 27, 2021)
 

書評

最近チェックした商品履歴

Loading...